82 results on '"Thierry Sulpice"'
Search Results
2. Ephrin-B1 regulates the adult diastolic function through a late postnatal maturation of cardiomyocyte surface crests
- Author
-
Clement Karsenty, Celine Guilbeau-Frugier, Gaël Genet, Marie-Helene Seguelas, Philippe Alzieu, Olivier Cazorla, Alexandra Montagner, Yuna Blum, Caroline Dubroca, Julile Maupoint, Blandine Tramunt, Marie Cauquil, Thierry Sulpice, Sylvain Richard, Silvia Arcucci, Remy Flores-Flores, Nicolas Pataluch, Romain Montoriol, Pierre Sicard, Antoine Deney, Thierry Couffinhal, Jean-Michel Senard, and Celine Galés
- Subjects
cardiac postnatal devleopment ,cardiomyocyte architecture ,subsarcolemmal mitochondria ,cardiac hypertrophy ,diatolic function ,ephrin-B1 ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
The rod-shaped adult cardiomyocyte (CM) harbors a unique architecture of its lateral surface with periodic crests, relying on the presence of subsarcolemmal mitochondria (SSM) with unknown role. Here, we investigated the development and functional role of CM crests during the postnatal period. We found in rodents that CM crest maturation occurs late between postnatal day 20 (P20) and P60 through both SSM biogenesis, swelling and crest-crest lateral interactions between adjacent CM, promoting tissue compaction. At the functional level, we showed that the P20-P60 period is dedicated to the improvement of relaxation. Interestingly, crest maturation specifically contributes to an atypical CM hypertrophy of its short axis, without myofibril addition, but relying on CM lateral stretching. Mechanistically, using constitutive and conditional CM-specific knock-out mice, we identified ephrin-B1, a lateral membrane stabilizer, as a molecular determinant of P20-P60 crest maturation, governing both the CM lateral stretch and the diastolic function, thus highly suggesting a link between crest maturity and diastole. Remarkably, while young adult CM-specific Efnb1 KO mice essentially exhibit an impairment of the ventricular diastole with preserved ejection fraction and exercise intolerance, they progressively switch toward systolic heart failure with 100% KO mice dying after 13 months, indicative of a critical role of CM-ephrin-B1 in the adult heart function. This study highlights the molecular determinants and the biological implication of a new late P20-P60 postnatal developmental stage of the heart in rodents during which, in part, ephrin-B1 specifically regulates the maturation of the CM surface crests and of the diastolic function.
- Published
- 2023
- Full Text
- View/download PDF
3. Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters
- Author
-
Valentin Sencio, Arnaud Machelart, Cyril Robil, Nicolas Benech, Eik Hoffmann, Chloé Galbert, Lucie Deryuter, Séverine Heumel, Aline Hantute-Ghesquier, Anne Flourens, Priscille Brodin, Fabrice Infanti, Virgile Richard, Jean Dubuisson, Corinne Grangette, Thierry Sulpice, Isabelle Wolowczuk, Florence Pinet, Vincent Prévot, Sandrine Belouzard, François Briand, Martine Duterque-Coquillaud, Harry Sokol, and François Trottein
- Subjects
sars-cov-2 ,covid-19 ,hamsters ,gut microbiota ,markers of disease severity ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Mounting evidence suggests that the gut-to-lung axis is critical during respiratory viral infections. We herein hypothesized that disruption of gut homeostasis during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may associate with early disease outcomes. To address this question, we took advantage of the Syrian hamster model. Our data confirmed that this model recapitulates some hallmark features of the human disease in the lungs. We further showed that SARS-CoV-2 infection associated with mild intestinal inflammation, relative alteration in intestinal barrier property and liver inflammation and altered lipid metabolism. These changes occurred concomitantly with an alteration of the gut microbiota composition over the course of infection, notably characterized by a higher relative abundance of deleterious bacterial taxa such as Enterobacteriaceae and Desulfovibrionaceae. Conversely, several members of the Ruminococcaceae and Lachnospiraceae families, including bacteria known to produce the fermentative products short-chain fatty acids (SCFAs), had a reduced relative proportion compared to non-infected controls. Accordingly, infection led to a transient decrease in systemic SCFA amounts. SCFA supplementation during infection had no effect on clinical and inflammatory parameters. Lastly, a strong correlation between some gut microbiota taxa and clinical and inflammation indices of SARS-CoV-2 infection severity was evidenced. Collectively, alteration of the gut microbiota correlates with disease severity in hamsters making this experimental model valuable for the design of interventional, gut microbiota-targeted, approaches for the control of COVID-19. Abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; SCFAs, short-chain fatty acids; dpi, day post-infection; RT-PCR, reverse transcription polymerase chain reaction; IL, interleukin. ACE2, angiotensin converting enzyme 2; TMPRSS2, transmembrane serine protease 2.
- Published
- 2022
- Full Text
- View/download PDF
4. Alteration of the gut microbiota’s composition and metabolic output correlates with COVID-19-like severity in obese NASH hamsters
- Author
-
Valentin Sencio, Nicolas Benech, Cyril Robil, Lucie Deruyter, Séverine Heumel, Arnaud Machelart, Thierry Sulpice, Antonin Lamazière, Corinne Grangette, François Briand, Harry Sokol, and François Trottein
- Subjects
SARS-CoV-2 ,hamsters ,gut microbiota ,obesity ,NASH ,COVID-19 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Obese patientss with nonalcoholic steatohepatitis (NASH) are particularly prone to developing severe forms of coronavirus disease 19 (COVID-19). The gut-to-lung axis is critical during viral infections of the respiratory tract, and a change in the gut microbiota’s composition might have a critical role in disease severity. Here, we investigated the consequences of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the gut microbiota in the context of obesity and NASH. To this end, we set up a nutritional model of obesity with dyslipidemia and NASH in the golden hamster, a relevant preclinical model of COVID-19. Relative to lean non-NASH controls, obese NASH hamsters develop severe inflammation of the lungs and liver. 16S rRNA gene profiling showed that depending on the diet, SARS-CoV-2 infection induced various changes in the gut microbiota’s composition. Changes were more prominent and transient at day 4 post-infection in lean animals, alterations still persisted at day 10 in obese NASH animals. A targeted, quantitative metabolomic analysis revealed changes in the gut microbiota’s metabolic output, some of which were diet-specific and regulated over time. Our results showed that specifically diet-associated taxa are correlated with disease parameters. Correlations between infection variables and diet-associated taxa highlighted a number of potentially protective or harmful bacteria in SARS-CoV-2-infected hamsters. In particular, some taxa in obese NASH hamsters (e.g. Blautia and Peptococcus) were associated with pro-inflammatory parameters in both the lungs and the liver. These taxon profiles and their association with specific disease markers suggest that microbial patterns might influence COVID-19 outcomes.
- Published
- 2022
- Full Text
- View/download PDF
5. Highly Diluted Antibodies to eNOS Restore Endothelium Function in Aortic Rings From Hypertensive Rats
- Author
-
Nataliya V. Petrova, Sergey A. Tarasov, Oleg I. Epstein, Caroline Dubroca, and Thierry Sulpice
- Subjects
Therapeutics. Pharmacology ,RM1-950 - Abstract
Background Nitric oxide (NO) as a vaso- and cardio-protective agent could reduce vasomotor dysfunction in different cardiovascular diseases. One of the current therapeutics targeted at NO availability in the vascular wall are highly diluted antibodies to endothelial NO-synthase (eNOS). This drug has previously shown its endothelium-protective effect and effectiveness in reducing hypertension. Current study was dedicated to evaluate the direct impact of highly diluted antibodies to eNOS on the vessel constriction and dilation ex vivo. Methods For that purpose, we used thoracic aortas dissected from spontaneously hypertensive (SHR) rats. Endothelium-dependent relaxation in the presence of highly diluted antibodies to eNOS (1 mL) was examined after phenylephrine-induced pre-constriction of the aorta rings in response to gradually increased acetylcholine concentration (1 nM to 10 µM). Results Highly diluted antibodies to eNOS enhanced acetylcholine-induced relaxation in a statistically significant manner. Moreover, it was demonstrated that observed effect was similar to perindopril, a well-known angiotensin-converting-enzyme inhibitor, which works through relaxing and widening blood vessels. Conclusions Our findings indicate that highly diluted antibodies to eNOS restored impaired endothelium function, as demonstrated by increased relaxation of SHR rats aorta rings. The revealed results suggest beneficial effect of highly diluted antibodies to eNOS to ameliorate hypertension and related diseases.
- Published
- 2022
- Full Text
- View/download PDF
6. A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death
- Author
-
François Briand, Christophe Heymes, Lucile Bonada, Thibault Angles, Julie Charpentier, Maxime Branchereau, Emmanuel Brousseau, Marjolaine Quinsat, Nicolas Fazilleau, Rémy Burcelin, and Thierry Sulpice
- Subjects
Therapeutics. Pharmacology ,RM1-950 ,Public aspects of medicine ,RA1-1270 - Abstract
The long duration of animal models represents a clear limitation to quickly evaluate the efficacy of drugs targeting nonalcoholic steatohepatitis (NASH). We, therefore, developed a rapid mouse model of liver inflammation (i.e., the mouse fed a high‐fat/high‐cholesterol diet, where cyclodextrin is co‐administered to favor hepatic cholesterol loading, liver inflammation, and NASH within 3 weeks), and evaluated the effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist elafibranor (ELA). C57BL6/J mice were fed a 60% high‐fat, 1.25% cholesterol, and 0.5% cholic acid diet with 2% cyclodextrin in drinking water (HFCC/CDX diet) for 3 weeks. After 1 week of the diet, mice were treated orally with vehicle or ELA 20 mg/kg q.d. for 2 weeks. Compared with vehicle, ELA markedly reduced liver lipids and nonalcoholic fatty liver disease activity scoring, through steatosis, inflammation, and fibrosis (all P
- Published
- 2020
- Full Text
- View/download PDF
7. Diet-Induced Obesity and NASH Impair Disease Recovery in SARS-CoV-2-Infected Golden Hamsters
- Author
-
François Briand, Valentin Sencio, Cyril Robil, Séverine Heumel, Lucie Deruyter, Arnaud Machelart, Johanna Barthelemy, Gemma Bogard, Eik Hoffmann, Fabrice Infanti, Oliver Domenig, Audrey Chabrat, Virgile Richard, Vincent Prévot, Ruben Nogueiras, Isabelle Wolowczuk, Florence Pinet, Thierry Sulpice, and François Trottein
- Subjects
obesity ,non-alcoholic steatohepatitis ,coronavirus disease 2019 ,SARS-CoV-2 ,hamster ,Microbiology ,QR1-502 - Abstract
Obese patients with non-alcoholic steatohepatitis (NASH) are prone to severe forms of COVID-19. There is an urgent need for new treatments that lower the severity of COVID-19 in this vulnerable population. To better replicate the human context, we set up a diet-induced model of obesity associated with dyslipidemia and NASH in the golden hamster (known to be a relevant preclinical model of COVID-19). A 20-week, free-choice diet induces obesity, dyslipidemia, and NASH (liver inflammation and fibrosis) in golden hamsters. Obese NASH hamsters have higher blood and pulmonary levels of inflammatory cytokines. In the early stages of a SARS-CoV-2 infection, the lung viral load and inflammation levels were similar in lean hamsters and obese NASH hamsters. However, obese NASH hamsters showed worse recovery (i.e., less resolution of lung inflammation 10 days post-infection (dpi) and lower body weight recovery on dpi 25). Obese NASH hamsters also exhibited higher levels of pulmonary fibrosis on dpi 25. Unlike lean animals, obese NASH hamsters infected with SARS-CoV-2 presented long-lasting dyslipidemia and systemic inflammation. Relative to lean controls, obese NASH hamsters had lower serum levels of angiotensin-converting enzyme 2 activity and higher serum levels of angiotensin II—a component known to favor inflammation and fibrosis. Even though the SARS-CoV-2 infection resulted in early weight loss and incomplete body weight recovery, obese NASH hamsters showed sustained liver steatosis, inflammation, hepatocyte ballooning, and marked liver fibrosis on dpi 25. We conclude that diet-induced obesity and NASH impair disease recovery in SARS-CoV-2-infected hamsters. This model might be of value for characterizing the pathophysiologic mechanisms of COVID-19 and evaluating the efficacy of treatments for the severe forms of COVID-19 observed in obese patients with NASH.
- Published
- 2022
- Full Text
- View/download PDF
8. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
- Author
-
Jose Castro-Perez, François Briand, Karen Gagen, Sheng-Ping Wang, Ying Chen, David G. McLaren, Vinit Shah, Rob J. Vreeken, Thomas Hankemeier, Thierry Sulpice, Thomas P. Roddy, Brian K. Hubbard, and Douglas G. Johns
- Subjects
cholesteryl ester transfer protein ,cholesterol efflux ,high density lipoprotein ,low density lipoprotein ,Biochemistry ,QD415-436 - Abstract
Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester (CE) and triglyceride between HDL and apoB-containing lipoproteins. Anacetrapib (ANA), a reversible inhibitor of CETP, raises HDL cholesterol (HDL-C) and lowers LDL cholesterol in dyslipidemic patients; however, the effects of ANA on cholesterol/lipoprotein metabolism in a dyslipidemic hamster model have not been demonstrated. To test whether ANA (60mg/kg/day, 2 weeks) promoted reverse cholesterol transport (RCT), 3H-cholesterol-loaded macrophages were injected and 3H-tracer levels were measured in HDL, liver, and feces. Compared to controls, ANA inhibited CETP (94%) and increased HDL-C (47%). 3H-tracer in HDL increased by 69% in hamsters treated with ANA, suggesting increased cholesterol efflux from macrophages to HDL. 3H-tracer in fecal cholesterol and bile acids increased by 90% and 57%, respectively, indicating increased macrophage-to-feces RCT. Mass spectrometry analysis of HDL from ANA-treated hamsters revealed an increase in free unlabeled cholesterol and CE. Furthermore, bulk cholesterol and cholic acid were increased in feces from ANA-treated hamsters. Using two independent approaches to assess cholesterol metabolism, the current study demonstrates that CETP inhibition with ANA promotes macrophage-to-feces RCT and results in increased fecal cholesterol/bile acid excretion, further supporting its development as a novel lipid therapy for the treatment of dyslipidemia and atherosclerotic vascular disease.
- Published
- 2011
- Full Text
- View/download PDF
9. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model
- Author
-
François Briand, Morgan Tréguier, Agnès André, Didier Grillot, Marc Issandou, Khadija Ouguerram, and Thierry Sulpice
- Subjects
cholesteryl ester transfer protein ,lipoprotein ,dyslipidemia ,atherosclerosis ,Biochemistry ,QD415-436 - Abstract
Liver X receptor (LXR) activation promotes reverse cholesterol transport (RCT) in rodents but has major side effects (increased triglycerides and LDL-cholesterol levels) in species expressing cholesteryl ester transfer protein (CETP). In the face of dyslipidemia, it remains unclear whether LXR activation stimulates RCT in CETP species. We therefore used a hamster model made dyslipidemic with a 0.3% cholesterol diet and treated with vehicle or LXR agonist GW3965 (30 mg/kg bid) over 10 days. To investigate RCT, radiolabeled 3H-cholesterol macrophages or 3H-cholesteryl oleate-HDL were then injected to measure plasma and feces radioactivity over 72 or 48 h, respectively. The cholesterol-enriched diet increased VLDL-triglycerides and total cholesterol levels in all lipoprotein fractions and strongly increased liver lipids. Overall, GW3965 failed to improve both dyslipidemia and liver steatosis. However, after 3H-cholesterol labeled macrophage injection, GW3965 treatment significantly increased the 3H-tracer appearance by 30% in plasma over 72 h, while fecal 3H-cholesterol excretion increased by 156% (P < 0.001). After 3H-cholesteryl oleate-HDL injection, GW3965 increased HDL-derived cholesterol fecal excretion by 64% (P < 0.01 vs. vehicle), while plasma fractional catabolic rate remained unchanged. Despite no beneficial effect on dyslipidemia, LXR activation promotes macrophage-to-feces RCT in dyslipidemic hamsters. These results emphasize the use of species with a more human-like lipoprotein metabolism for drug profiling.
- Published
- 2010
- Full Text
- View/download PDF
10. Deletion of apoptosis signal-regulating kinase 1 (ASK1) protects pancreatic beta-cells from stress-induced death but not from glucose homeostasis alterations under pro-inflammatory conditions.
- Author
-
Emilie Pepin, Arisa Higa, Carole Schuster-Klein, Catherine Bernard, Thierry Sulpice, Beatrice Guardiola, Eric Chevet, and Thierry Alquier
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Type 2 diabetes is characterized by pancreatic beta-cell dysfunction and is associated with low-grade inflammation. Recent observations suggest that apoptosis signal-regulating kinase 1 (ASK1) is involved in beta-cell death in response to different stressors. In this study, we tested whether ASK1 deficiency protects beta-cells from glucolipotoxic conditions and cytokines treatment or from glucose homeostasis alteration induced by endotoxemia. METHODOLOGY/PRINCIPAL FINDINGS:Insulin secretion was neither affected upon shRNA-mediated downregulation of ASK1 in MIN6 cells nor in islets from ASK1-deficient mice. ASK1 silencing in MIN6 cells and deletion in islets did not prevent the deleterious effect of glucolipotoxic conditions or cytokines on insulin secretion. However, it protected MIN6 cells from death induced by ER stress or palmitate and islets from short term caspase activation in response to cytokines. Moreover, endotoxemia induced by LPS infusion increased insulin secretion during hyperglycemic clamps but the response was similar in wild-type and ASK1-deficient mice. Finally, insulin sensitivity in the presence of LPS was not affected by ASK1-deficiency. CONCLUSIONS/SIGNIFICANCE:Our study demonstrates that ASK1 is not involved in beta-cell function and dysfunction but controls stress-induced beta-cell death.
- Published
- 2014
- Full Text
- View/download PDF
11. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass.
- Author
-
Amandine Girousse, Geneviève Tavernier, Carine Valle, Cedric Moro, Niklas Mejhert, Anne-Laure Dinel, Marianne Houssier, Balbine Roussel, Aurèle Besse-Patin, Marion Combes, Lucile Mir, Laurent Monbrun, Véronic Bézaire, Bénédicte Prunet-Marcassus, Aurélie Waget, Isabelle Vila, Sylvie Caspar-Bauguil, Katie Louche, Marie-Adeline Marques, Aline Mairal, Marie-Laure Renoud, Jean Galitzky, Cecilia Holm, Etienne Mouisel, Claire Thalamas, Nathalie Viguerie, Thierry Sulpice, Rémy Burcelin, Peter Arner, and Dominique Langin
- Subjects
Biology (General) ,QH301-705.5 - Abstract
When energy is needed, white adipose tissue (WAT) provides fatty acids (FAs) for use in peripheral tissues via stimulation of fat cell lipolysis. FAs have been postulated to play a critical role in the development of obesity-induced insulin resistance, a major risk factor for diabetes and cardiovascular disease. However, whether and how chronic inhibition of fat mobilization from WAT modulates insulin sensitivity remains elusive. Hormone-sensitive lipase (HSL) participates in the breakdown of WAT triacylglycerol into FAs. HSL haploinsufficiency and treatment with a HSL inhibitor resulted in improvement of insulin tolerance without impact on body weight, fat mass, and WAT inflammation in high-fat-diet-fed mice. In vivo palmitate turnover analysis revealed that blunted lipolytic capacity is associated with diminution in FA uptake and storage in peripheral tissues of obese HSL haploinsufficient mice. The reduction in FA turnover was accompanied by an improvement of glucose metabolism with a shift in respiratory quotient, increase of glucose uptake in WAT and skeletal muscle, and enhancement of de novo lipogenesis and insulin signalling in liver. In human adipocytes, HSL gene silencing led to improved insulin-stimulated glucose uptake, resulting in increased de novo lipogenesis and activation of cognate gene expression. In clinical studies, WAT lipolytic rate was positively and negatively correlated with indexes of insulin resistance and WAT de novo lipogenesis gene expression, respectively. In obese individuals, chronic inhibition of lipolysis resulted in induction of WAT de novo lipogenesis gene expression. Thus, reduction in WAT lipolysis reshapes FA fluxes without increase of fat mass and improves glucose metabolism through cell-autonomous induction of fat cell de novo lipogenesis, which contributes to improved insulin sensitivity.
- Published
- 2013
- Full Text
- View/download PDF
12. Author response: Ephrin-B1 regulates the adult diastolic function through a late postnatal maturation of cardiomyocyte surface crests
- Author
-
Clement Karsenty, Celine Guilbeau-Frugier, Gaël Genet, Marie-Helene Seguelas, Philippe Alzieu, Olivier Cazorla, Alexandra Montagner, Yuna Blum, Caroline Dubroca, Julile Maupoint, Blandine Tramunt, Marie Cauquil, Thierry Sulpice, Sylvain Richard, Silvia Arcucci, Remy Flores-Flores, Nicolas Pataluch, Romain Montoriol, Pierre Sicard, Antoine Deney, Thierry Couffinhal, Jean-Michel Senard, and Celine Galés
- Published
- 2022
13. Empagliflozin Improves Heart Failure with Preserved Ejection Fraction Despite Limited Effects on NASH in Non-diabetic and Diabetic Diet-induced Obese Hamsters
- Author
-
François Briand, Julie Maupoint, Caroline Dubroca, and Thierry Sulpice
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism - Published
- 2023
14. 272-OR: Weight Loss with Time-Restricted Feeding or Treatment with Obeticholic Acid/Semaglutide Combination Have a Different Impact on Nonalcoholic Steatohepatitis in Diet-Induced Obese Mice
- Author
-
FRANCOIS BRIAND, ESTELLE GRASSET, NATALIA BREYNER, and THIERRY SULPICE
- Subjects
Endocrinology, Diabetes and Metabolism ,Internal Medicine - Abstract
Introduction: Combination of therapies is a promising strategy for the treatment of NASH and liver fibrosis. Here we evaluated whether the Farnesoid X Receptor agonist obeticholic acid (OCA) combined with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (SEMA) would show superior effects than weight loss induction with time-restricted feeding (TRF) in mice. Methods: Mice were fed a 60% high fat/2% cholesterol diet with 10% fructose supplemented drinking water (HFCF diet) for 25 weeks to induce obesity and NASH/liver fibrosis. After the diet-induction period, mice were kept on HFCF diet and treated with vehicle (control) or OCA 30mg/kg p.o. QD + SEMA 0.06mg/kg s.c. QD, or placed on TRF from the last 3 hours of the dark cycle till the end of the light cycle, without access to food, but free access to normal drinking water (i.e. without fructose) every day, for 6 weeks. Results: OCA+SEMA induced a 20% lower caloric intake, which led to a 27% lower body weight (p Conclusion: OCA+SEMA combination reduced body weight and NAFLD activity score but did not improve hepatic fibrosis, while TRF improved both NASH and liver fibrosis. These TRF benefits should be further investigated in obese NASH patients. Disclosure F.Briand: None. E.Grasset: None. N.Breyner: None. T.Sulpice: None.
- Published
- 2022
15. MO615: The Lund Mets Rat, An Obese Type 2 Diabetic Preclinical Model, Develops Non-Alcoholic Steatohepatitis, Diabetic Nephropathy and Heart Failure with Preserved Ejection Fraction Under High Fat/Cholesterol/Fructose Diet
- Author
-
Francois Briand, Caroline Dubroca, Julie Maupoint, Emmanuel Brousseau, and Thierry Sulpice
- Subjects
Transplantation ,Nephrology - Abstract
BACKGROUND AND AIMS Beyond the glucose control, anti-diabetic drugs need to demonstrate benefits on metabolic comorbidities. An animal model that recapitulates obesity and type 2 diabetes (T2D) comorbidities [i.e. non-alcoholic steato-hepatitis (NASH), nephropathy and heart failure with preserved ejection fraction (HFpEF)] is still needed for preclinical drug development. To overcome this limitation, we evaluated the effects of a high fat/cholesterol/fructose (HFCF) diet in the Lund MetS rat, a congenic BBDR.cg-lepr.cp model generated by introgression of the Koletsky leptin receptor mutation into the BioBreeding Diabetes Resistant (BBDR) rat. METHOD 17-week-old, male, lean control (ctrl) or Lund MetS obese T2D rats were fed a control chow (CC) diet or a HFCF diet, respectively for 8 weeks. Blood biochemistry was measured at 0, 4 and 8 weeks of diet. Kidney, heart and liver parameters were assessed at the end of the 8-week diet period. RESULTS Compared with ctrl, Lund MetS rats were obese (56% higher body weight) and diabetic with significantly higher %HbA1c (up to + 3%) and blood glucose levels (up to 3-fold higher) during the 8-week HFCF diet period. Significantly higher plasma insulin (up to 11-fold), total cholesterol (up to 5-fold), triglycerides (up to 8-fold), transaminases (up to 10-fold higher) levels were also observed in Lund MetS rats, as compared with ctrl. Hepatic total cholesterol, triglycerides and fatty acids levels were significantly higher in Lund Mets rats (14-, 7.3- and 6.7-fold higher as compared to ctrl, respectively). Liver histopathological scoring confirmed a NASH phenotype in Lund MetS rats fed the HFCF diet with strong liver steatosis, hepatic inflammation and portal to bridging fibrosis. Kidney function was substantially altered with a 60% decline in glomerular filtration rate and a 16-fold increase in urine albumin-to-creatinine ratio (both P CONCLUSION The present data demonstrate that the Lund MetS rat fed an HFCF diet that recapitulates the major metabolic comorbidities of obesity/T2D and may be a useful model for preclinical drug development.
- Published
- 2022
16. MO617: Liraglutide Improves Both Diabetic Nephropathy and Cardiomyopathy in the SDT Fatty Rat, A Cardiorenal Model of Type 2 Diabetes
- Author
-
Francois Briand, Masami Shinohara, Emmanuel Brousseau, Julie Maupoint, Caroline Dubroca, Yasushi Kageyama, and Thierry Sulpice
- Subjects
Transplantation ,Nephrology - Abstract
BACKGROUND AND AIMS The Glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide (LIRA) has cardioprotective effects and may reduce the development of kidney disease in type 2 diabetic patients. We here evaluated the effects of LIRA on both kidney and heart function in the Spontaneously Diabetic Torii (SDT) fatty rat, a type 2 diabetic cardiorenal model. METHOD SDT fatty male rats were treated subcutaneously with vehicle or LIRA 0.4 mg/kg QD for 10 weeks. To measure the effects of LIRA on glomerular hyperfiltration, rats were injected with FITC-sinistrin to measure glomerular filtration rate (GFR) at 4 weeks of treatment. At 5 weeks of treatment, rats underwent unilateral nephrectomy and were put on a 0.3% salt diet to induce a GFR decline. GFR was then measured at 10 weeks of treatment, before hemodynamics measurement and echocardiography. RESULTS Compared with vehicle, LIRA induced significant body weight loss, as well as blood glucose levels reduction by up to ∼20%. During the hyperfiltration phase, LIRA attenuated hyperfiltration, with a 19% lower GFR versus vehicle (P CONCLUSION In the SDT fatty rat, LIRA shows significant benefits by reducing renal hyperfiltration, preventing GFR decline, and improving cardiac hypertrophy, blood pressure and diastolic dysfunction. This preclinical model will be useful to evaluate drugs targeting the cardiorenal axis in type 2 diabetes.
- Published
- 2022
17. Abstract 112: Sars-cov-2 Infection Promotes Dyslipidemia And Non-alcoholic Steatohepatitis In Diet-induced Obese Golden Syrian Hamsters
- Author
-
Francois Briand, Valentin Sencio, Thierry SULPICE, and François Trottein
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background: Obesity, non-alcoholic steatohepatitis (NASH) and dyslipidemia have been associated with severe forms of COVID-19. To better understand the impact of SARS-CoV-2 infection on dyslipidemia and NASH, we investigated the impact of infection with the beta variant of the SARS-CoV-2 in lean and high fat/cholesterol/fructose diet-induced obese Golden Syrian hamsters. Methods: Lean (chow diet fed) or diet-induced obese hamsters were infected intranasally with the beta variant of the SARS-CoV-2. At baseline (before infection) and at 4-, 7-, 10- and 25-days post-infection (dpi), blood and organs were collected for biochemistry and histology analyses. Results: Early after SARS-CoV-2 infection, lung viral load and pulmonary inflammation were not different between lean and obese hamsters. However, compared to lean hamsters, obese hamsters showed significantly higher MCP-1 serum levels at baseline and after infection, had impaired recovery (lower resolution of lung lesions at 10 dpi, lower body weight regain at 25 dpi), and exhibited higher pulmonary fibrosis at 25 dpi. In both lean and obese hamsters, SARS-CoV-2 infection led to reduction in serum triglycerides and HDL-cholesterol levels at 4 and 7 dpi. However, obese hamsters remained hypertriglyceridemic and hypercholesterolemic, while SARS-CoV-2 infection led to significant elevation of serum free fatty acids and LDL-cholesterol levels at 4 and 7 dpi in those obese individuals, as compared to baseline levels. Despite the substantial weight loss induced by SARS-CoV-2 infection, the NASH phenotype of obese hamsters was maintained, with significantly higher liver steatosis, inflammation, hepatocyte ballooning and fibrosis scores from day 0 to 25 dpi. Additionally, obese hamsters showed significantly higher liver fibrosis at 25 dpi, as compared to lean hamsters. Conclusion: Our data indicate that SARS-CoV-2 infection promotes dyslipidemia and non-alcoholic steatohepatitis in diet-induced obese Golden Syrian hamsters. This model will be useful to investigate the mechanisms leading to severe forms of COVID-19 seen in obese patients with dyslipidemia and NASH.
- Published
- 2022
18. Crest maturation at the cardiomyocyte surface contributes to a new late postnatal development stage that controls the diastolic function of the adult heart
- Author
-
Clément Karsenty, Céline Guilbeau-Frugier, Gaël Genet, Marie-Hélène Seguelas, Philippe Alzieu, Olivier Cazorla, Alexandra Montagner, Yuna Blum, Caroline Dubroca, Julie Maupoint, Blandine Tramunt, Marie Cauquil, Thierry Sulpice, Sylvain Richard, Silvia Arcucci, Remy Flores-Flores, Nicolas Pataluch, Romain Montoriol, Pierre Sicard, Antoine Deney, Thierry Couffinhal, Jean-Michel Sénard, Céline Galés, Institut des Maladies Métaboliques et Casdiovasculaires (UPS/Inserm U1297 - I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), University of Virginia School of Medicine [US], Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases, Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Toulouse (UT), and CHU Bordeaux [Bordeaux]
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
RATIONALEIn addition to its typical rod-shape, the mammalian adult cardiomyocyte (CM) harbors a unique lateral membrane surface architecture with periodic crests, relying on the presence of subsarcolemmal mitochondria (SSM) the role of which is still unknown.OBJECTIVETo investigate the development and functional role of CM crests during the postnatal period.METHODS AND RESULTSElectron/confocal microscopy and western-blot of left ventricular tissues from rat hearts indicated a late CM surface crest maturation, between postnatal day 20 (P20) and P60, as shown by substantial SSM swelling and increased claudin-5 cell surface expression. The P20-P60 postnatal stage also correlates with an ultimate maturation of the T-Tubules and the intercalated disk. At the cellular level, we identified an atypical CM hypertrophy characterized by an increase in long- and short-axes without myofibril addition and with sarcomere lateral stretching, indicative of lateral stretch-based CM hypertrophy. We confirmed the P20-P60 hypertrophy at the organ level by echocardiography but also demonstrated a transcriptomic program after P20 targeting all the cardiac cell populations. At the functional level, using Doppler echocardiography, we found that the P20-P60 period is specifically dedicated to the improvement of relaxation. Mechanistically, using CM-specific knock-out mice, we identified ephrin-B1 as a determinant of CM crest maturation after P20 controlling lateral CM stretch-hypertrophy and relaxation. Interestingly, while young adultEfnb1CMspe−/−mice essentially show a relaxation impairment with exercise intolerance, they progressively switch toward heart failure with 100% KO mice dying after 13 months.CONCLUSIONSThis study highlights a new late P20-P60 postnatal developmental stage of the heart in rodents during which the CM surface crests mature through an ephrin-B1-dependant mechanism and regulate the diastolic function. Moreover, we demonstrate for the first time that the CM crest architecture is cardioprotective.
- Published
- 2022
19. The Hepatic Compensatory Response to Elevated Systemic Sulfide Promotes Diabetes
- Author
-
Thierry Sulpice, Martin E. Barrios-Llerena, Matthew T G Gibbins, Ruma Banerjee, Thomas H. Gillingwater, Madara Brice, Gillian A. Gray, Huizhong Su, Nicholas M. Morton, Anne Tailleux, Subhankar Singha, Colin Selman, Peter L. Freddolino, Natalie Z.M. Homer, Clare Mc Fadden, Claire McMaster, Marouane Libiad, Kyo Han Ahn, Stephen E. Wilkie, François Briand, Roderick N. Carter, Victor Vitvitsky, Nourdine Faresse, Thierry Le Bihan, Bart Staels, Scott G. Denham, Barry Emerson, Richard C. Hartley, and Andrew J. Finch
- Subjects
Male ,persulfidation ,medicine.medical_specialty ,Proteome ,Sulfide ,NF-E2-Related Factor 2 ,thiosulfate sulfur transferase ,Context (language use) ,Sulfides ,Article ,General Biochemistry, Genetics and Molecular Biology ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Diabetes Mellitus ,medicine ,Animals ,insulin sensitivity ,sulfide oxidation pathway ,sulfide donor ,Beta oxidation ,Dyslipidemias ,fatty liver ,030304 developmental biology ,Mice, Knockout ,chemistry.chemical_classification ,0303 health sciences ,sulfide ,Chemistry ,Fatty liver ,Gluconeogenesis ,TST ,Lipid metabolism ,Metabolism ,Lipid Metabolism ,medicine.disease ,Thiosulfate Sulfurtransferase ,Mice, Inbred C57BL ,Glucose ,Endocrinology ,Liver ,type 2 diabetes ,Liver function ,Thiosulfate sulfurtransferase ,Drug metabolism ,030217 neurology & neurosurgery ,Homeostasis - Abstract
Summary Impaired hepatic glucose and lipid metabolism are hallmarks of type 2 diabetes. Increased sulfide production or sulfide donor compounds may beneficially regulate hepatic metabolism. Disposal of sulfide through the sulfide oxidation pathway (SOP) is critical for maintaining sulfide within a safe physiological range. We show that mice lacking the liver- enriched mitochondrial SOP enzyme thiosulfate sulfurtransferase (Tst−/− mice) exhibit high circulating sulfide, increased gluconeogenesis, hypertriglyceridemia, and fatty liver. Unexpectedly, hepatic sulfide levels are normal in Tst−/− mice because of exaggerated induction of sulfide disposal, with associated suppression of global protein persulfidation and nuclear respiratory factor 2 target protein levels. Hepatic proteomic and persulfidomic profiles converge on gluconeogenesis and lipid metabolism, revealing a selective deficit in medium-chain fatty acid oxidation in Tst−/− mice. We reveal a critical role of TST in hepatic metabolism that has implications for sulfide donor strategies in the context of metabolic disease., Graphical abstract, Highlights • TST deficiency elevates sulfide, invoking exaggerated hepatic sulfide disposal • Exaggerated sulfide disposal triggers global hepatic protein underpersulfidation • Skewed persulfidation is associated with higher gluconeogenesis and impaired fat oxidation • Diabetogenic hepatic metabolism dominates over apparent peripheral insulin sensitization, Carter et al. show that mice lacking the mitochondrial sulfide oxidation pathway enzyme TST have high systemic sulfide levels that invoke an alternative hepatic sulfide disposal strategy. Consequently, hepatic metabolism is dominantly skewed toward a diabetogenic profile despite peripheral insulin sensitization. This has implications for sulfide donor therapeutic agents.
- Published
- 2021
20. Weight loss with semaglutide treatment or time-restricted feeding differentially improves non-alcoholic steatohepatitis in diet-induced obese insulin resistant mice
- Author
-
Francois Briand, Estelle Grasset, Natalia Breyner, and Thierry Sulpice
- Subjects
Hepatology - Published
- 2022
21. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters
- Author
-
Emmanuel Brousseau, Rémy Burcelin, Thierry Sulpice, Virgile Richard, Mélanie Bouchet, Thierry Leste-Lasserre, Audrey Chabrat, Natalia Breyner, Clément Costard, Mathieu Petitjean, Li Chen, Julie Maupoint, François Briand, Caroline Dubroca, Physiogenex, Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Casdiovasculaires (UPS/Inserm U1297 - I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Rangueil, and CHU Toulouse [Toulouse]
- Subjects
Liver Cirrhosis ,Male ,0301 basic medicine ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Diastole ,Hamster ,030209 endocrinology & metabolism ,Heart failure ,Fructose ,Diet, High-Fat ,digestive system ,03 medical and health sciences ,Chalcones ,0302 clinical medicine ,Endocrinology ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Non-alcoholic Fatty Liver Disease ,Fibrosis ,Internal medicine ,medicine ,Animals ,PPAR alpha ,PPAR delta ,Nonalcoholic steatohepatitis ,Ejection fraction ,Mesocricetus ,business.industry ,Elafibranor ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,medicine.disease ,digestive system diseases ,Disease Models, Animal ,Cholesterol ,030104 developmental biology ,Liver ,Hepatocytes ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Diastolic dysfunction ,Peroxisome proliferator-activated receptor alpha ,Propionates ,business ,Heart failure with preserved ejection fraction - Abstract
International audience; Background: Cardiovascular disease is the leading cause of deaths in nonalcoholic steatohepatitis (NASH) patients. Mouse models, while widely used for drug development, do not fully replicate human NASH nor integrate the associated cardiac dysfunction, i.e. heart failure with preserved ejection fraction (HFpEF). To overcome these limitations, we established a nutritional hamster model developing both NASH and HFpEF. We then evaluated the effects of the dual peroxisome proliferator activated receptor alpha/delta agonist elafibranor developed for the treatment of NASH patients.Methods: Male Golden Syrian hamsters were fed for 10 to 20 weeks with a free choice diet, which presents hamsters with a choice between control chow diet with normal drinking water or a high fat/high cholesterol diet with 10% fructose enriched drinking water. Biochemistry, histology and echocardiography analysis were performed to characterize NASH and HFpEF. Once the model was validated, elafibranor was evaluated at 15 mg/kg/day orally QD for 5 weeks.Results: Hamsters fed a free choice diet for up to 20 weeks developed NASH, including hepatocyte ballooning (as confirmed with cytokeratin-18 immunostaining), bridging fibrosis, and a severe diastolic dysfunction with restrictive profile, but preserved ejection fraction. Elafibranor resolved NASH, with significant reduction in ballooning and fibrosis scores, and improved diastolic dysfunction with significant reduction in E/A and E/E' ratios.Conclusion: Our data demonstrate that the free choice diet induced NASH hamster model replicates the human phenotype and will be useful for validating novel drug candidates for the treatment of NASH and associated HfpEF.
- Published
- 2021
22. CX3CR1 regulates gut microbiota and metabolism. A risk factor of type 2 diabetes
- Author
-
Thierry Sulpice, Rémy Burcelin, François Briand, Aurélie Waget, Vincent Azalbert, Lucile Garidou, Céline Garret, Céline Pomié, Benjamin Lelouvier, Julie Charpentier, Pascale Klopp, Florence Servant, and Victorine Douin-Echinard
- Subjects
Glucose tolerance test ,medicine.diagnostic_test ,Endocrinology, Diabetes and Metabolism ,Prebiotic ,medicine.medical_treatment ,030209 endocrinology & metabolism ,General Medicine ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Biology ,Gut flora ,medicine.disease ,biology.organism_classification ,digestive system ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Immune system ,Diabetes mellitus ,Immunology ,Internal Medicine ,medicine ,Dysbiosis ,Glycemic - Abstract
The intestinal microbiota to immune system crosstalk is a major regulator of metabolism and hence metabolic diseases. An impairment of the chemokine receptor CX3CR1, as a key regulator shaping intestinal microbiota under normal chow feeding, could be one of the early events of dysglycemia. We studied the gut microbiota ecology by sequencing the gut and tissue microbiota. We studied its role in energy metabolism in CX3CR1-deficent and control mice using various bioassays notably the glycemic regulation during fasting and the respiratory quotient as two highly sensitive physiological features. We used antibiotics and prebiotics treatments, and germ free mouse colonization. We identify that CX3CR1 disruption impairs gut microbiota ecology and identified a specific signature associated to the genotype. The glycemic control during fasting and the respiratory quotient throughout the day are deeply impaired. A selected four-week prebiotic treatment modifies the dysbiotic microbiota and improves the fasting state glycemic control of the CX3CR1-deficent mice and following a glucose tolerance test. A 4 week antibiotic treatment also improves the glycemic control as well. Eventually, germ free mice colonized with the microbiota from CX3CR1-deficent mice developed glucose intolerance. CX3CR1 is a molecular mechanism in the control of the gut microbiota ecology ensuring the maintenance of a steady glycemia and energy metabolism. Its impairment could be an early mechanism leading to gut microbiota dysbiosis and the onset of metabolic disease.
- Published
- 2021
23. Diet-induced obesity and NASH aggravate SARS-CoV-2 infection in golden Syrian hamsters
- Author
-
François Briand, Valentin Sencio, Thierry Sulpice, and François Trottein
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism - Published
- 2022
24. Ezetimibe Enhances Macrophage-to-Feces Reverse Cholesterol Transport in Golden Syrian Hamsters Fed a High-Cholesterol Diet
- Author
-
Fatima Kasbi Chadli, Thierry Sulpice, Khadija Ouguerram, Morgan Tréguier, and François Briand
- Subjects
0301 basic medicine ,Male ,Very low-density lipoprotein ,medicine.medical_specialty ,medicine.medical_treatment ,Intraperitoneal injection ,Hamster ,ABCG8 ,Diet, High-Fat ,03 medical and health sciences ,chemistry.chemical_compound ,Feces ,0302 clinical medicine ,Ezetimibe ,Internal medicine ,Cricetinae ,medicine ,Animals ,Pharmacology ,Mesocricetus ,Cholesterol ,Anticholesteremic Agents ,Macrophages ,Reverse cholesterol transport ,Biological Transport ,Sterol ,Absorption, Physiological ,030104 developmental biology ,Endocrinology ,chemistry ,Liver ,Molecular Medicine ,lipids (amino acids, peptides, and proteins) ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The aim of this work was to evaluate reverse cholesterol transport (RCT) in hamster, animal model expressing CETP under a high cholesterol diet (HF) supplemented with Ezetimibe using primary labelled macrophages. We studied three groups of hamsters (n=8/group) for 4 weeks: 1) chow diet group: Chow, 2) High cholesterol diet group: HF and 3) HF group supplemented with 0.01% of ezetimibe: HF+0.01%Ezet. Following intraperitoneal injection of 3H-cholesterol-labelled hamster primary macrophages, we measured the in vivo macrophage-to-feces RCT. .HF group exhibited an increase of triglycerides (TG), cholesterol, glucose in plasma and higher TG and cholesterol content in liver (p
- Published
- 2020
25. 482-P: The GLP-1 Receptor Agonist Liraglutide Improves Glomerular Filtration Rate, Renal Inflammation, and Fibrosis in the Type 2 Diabetic SDT Fatty Rat
- Author
-
Yasushi Kageyama, Thierry Sulpice, Masami Shinohara, Emmanuel Brousseau, and François Briand
- Subjects
Agonist ,medicine.medical_specialty ,Liraglutide ,medicine.drug_class ,business.industry ,Endocrinology, Diabetes and Metabolism ,Renal function ,Urine ,Type 2 diabetes ,medicine.disease ,Endocrinology ,Fibrosis ,Internal medicine ,Internal Medicine ,medicine ,business ,Glucagon-like peptide 1 receptor ,Glomerular hyperfiltration ,medicine.drug - Abstract
The Glucagon-Like Peptide 1 (GLP-1) receptor agonist liraglutide (LIRA) may reduce the rate of development and progression of diabetic kidney disease in type 2 diabetic patients. To evaluate its impact on kidney function, we evaluated the effects of LIRA on glomerular filtration rate (GFR), in both the hyperfiltration and GFR decline phases in the Spontaneously Diabetic Torii (SDT) fatty rat, a preclinical model of type 2 diabetes. SDT fatty male rats were treated subcutaneously, once daily with vehicle or LIRA 0.4mg/kg for 10 weeks. To measure the effects of LIRA on glomerular hyperfiltration, rats were injected with FITC-sinistrin at 4 weeks of treatment to measure GFR. After 5 weeks of treatment, rats underwent unilateral nephrectomy and were put on a 0.3% salt diet to induce a GFR decline for the last weeks of treatment, then GFR was measured at 10 weeks of treatment. Urine biochemistry and kidney histology analysis were also performed. Compared with vehicle, LIRA resulted in significant body weight loss and lower body weight. LIRA also reduced blood glucose levels significantly by up to ∼20%, as expected. During the hyperfiltration phase, LIRA attenuated hyperfiltration, with a 19% lower GFR vs. vehicle (vehicle: 21 ± 1.1 mL/min/kg; LIRA: 17.1 ± 1.0 mL/min/kg, p In conclusion, LIRA shows significant benefits on GFR, renal inflammation and fibrosis in the SDT fatty rat model. Disclosure F. Briand: Employee; Self; Physiogenex. Stock/Shareholder; Self; Physiogenex. M. Shinohara: None. E. Brousseau: Employee; Self; Physiogenex. Y. Kageyama: None. T. Sulpice: Employee; Self; Physiogenex. Stock/Shareholder; Self; Physiogenex.
- Published
- 2020
26. A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death
- Author
-
Emmanuel Brousseau, Thierry Sulpice, Lucile Bonada, Marjolaine Quinsat, Thibault Angles, Rémy Burcelin, Julie Charpentier, François Briand, Nicolas Fazilleau, Maxime Branchereau, Christophe Heymes, PINIER, CHRISTINE, Physiogenex, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and CHU Toulouse [Toulouse]
- Subjects
Male ,030213 general clinical medicine ,medicine.medical_specialty ,Necroptosis ,Population ,Inflammation ,Apoptosis ,Diet, High-Fat ,030226 pharmacology & pharmacy ,General Biochemistry, Genetics and Molecular Biology ,Article ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Immune system ,Chalcones ,Non-alcoholic Fatty Liver Disease ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Animals ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,education ,education.field_of_study ,business.industry ,General Neuroscience ,Research ,lcsh:Public aspects of medicine ,lcsh:RM1-950 ,Elafibranor ,lcsh:RA1-1270 ,General Medicine ,Articles ,medicine.disease ,Natural killer T cell ,3. Good health ,Disease Models, Animal ,Endocrinology ,lcsh:Therapeutics. Pharmacology ,Liver ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,medicine.symptom ,Steatosis ,Propionates ,business - Abstract
International audience; The long duration of animal models represents a clear limitation to quickly evaluate the efficacy of drugs targeting nonalcoholic steatohepatitis (NASH). We, therefore, developed a rapid mouse model of liver inflammation (i.e., the mouse fed a high-fat/high-cholesterol diet, where cyclodextrin is co-administered to favor hepatic cholesterol loading, liver inflammation, and NASH within 3 weeks), and evaluated the effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist elafibranor (ELA). C57BL6/J mice were fed a 60% high-fat, 1.25% cholesterol, and 0.5% cholic acid diet with 2% cyclodextrin in drinking water (HFCC/CDX diet) for 3 weeks. After 1 week of the diet, mice were treated orally with vehicle or ELA 20 mg/kg q.d. for 2 weeks. Compared with vehicle, ELA markedly reduced liver lipids and nonalcoholic fatty liver disease activity scoring, through steatosis, inflammation, and fibrosis (all P < 0.01 vs. vehicle). Flow cytometry analysis showed that ELA significantly improved the HFCC/CDX diet-induced liver inflammation by preventing the increase in total number of immune cells (CD45+), Kupffer cells, dendritic cells, and monocytes population, as well as the reduction in natural killer and natural killer T cells, and by blocking conversion of T cells in regulatory T cells. ELA did not alter pyroptosis (Gasdermin D), but significantly reduced necroptosis (cleaved RIP3) and apoptosis (cleaved caspase 3) in the liver. In conclusion, ELA showed strong benefits on NASH, including improvement in hepatic inflammation, necroptosis, and apoptosis in the 3-week NASH mouse. This preclinical model will be useful to rapidly detect the effects of novel drugs targeting NASH.
- Published
- 2020
27. Étude de l’activité antidiabétique de Capparis spinosa L. et de Calamintha officinalis Moench chez la souris diabétique
- Author
-
Morad Hebi, Rémy Burcelin, Mohamed Eddouks, Mohammed Ajebli, A. El Hidani, and Thierry Sulpice
- Subjects
Pharmacology ,03 medical and health sciences ,010404 medicinal & biomolecular chemistry ,0302 clinical medicine ,Complementary and alternative medicine ,010405 organic chemistry ,030220 oncology & carcinogenesis ,01 natural sciences ,0104 chemical sciences - Abstract
Les activites antidiabetiques de Capparis spinosa (CS) et de Calamintha officinalis Moench (CO) ont ete evaluees sur un modele de souris de diabete de type 2 (HFD, high fat diet), presentant un etat prediabetique. L’administration des extraits aqueux bruts (coEA 100 mg/kg, csEA 100 mg/kg) et des extraits aqueux traites a la chaleur (coEAC 100 mg/kg, csEAC 100 mg/kg) pendant trois semaines a montre une activite antidiabetique, une baisse du poids ainsi qu’une baisse des concentrations plasmatiques d’acides gras circulants. Cette activite resiste au traitement a la chaleur. Les extraits bruts ont ete extraits par deux solvants differents, dichloromethane, butanol, produisant trois fractions de chaque extrait. Les activites antidiabetique et hypolipidemiante observees par traitement coEA (100 mg/kg) ont ete retrouvees chez les souris traitees avec la fraction eau residuelle (coER, 100 mg/kg) avec la meme efficacite, permettant d’affirmer que des molecules hydrophiles sont responsables des effets observes. L’activite antidiabetique observee chez les souris csEA (100 mg/kg) a ete retrouvee chez les souris traitees avec la fraction butanol (csBUT, 100 mg/kg) non correlee a l’activite hypolipidemiante retrouvee dans la fraction dichloromethane (csDC, 100 mg/kg), permettant d’affirmer que ces deux activites sont dues a des molecules lipophiles. Enfin, pour les deux plantes, l’activite sur le poids est retrouvee dans l’ensemble des fractions, ce qui montre que cette activite est due a des molecules de polarites differentes.
- Published
- 2018
28. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis
- Author
-
Laurent O. Martinez, Souad Najib, Thierry Sulpice, François Briand, Guillaume Combes, Thibaut Duparc, Jules Merian, Charlotte Trenteseaux, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiogenex, and Lifesearch SAS [Toulouse, France]
- Subjects
Liver Cirrhosis ,nonalcoholic fatty liver disease ,Physiology ,Pharmacology ,Systemic inflammation ,Gastroenterology ,Cholesterol, Dietary ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Fibrosis ,Non-alcoholic Fatty Liver Disease ,Nonalcoholic fatty liver disease ,Medicine ,nonalcoholic steatohepatitis ,0303 health sciences ,3. Good health ,Pre-clinical development ,2-Hydroxypropyl-beta-cyclodextrin ,Liver ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,medicine.symptom ,medicine.drug ,medicine.medical_specialty ,Cholic Acid ,Diet, High-Fat ,03 medical and health sciences ,Insulin resistance ,Metabolic Diseases ,Physiology (medical) ,Internal medicine ,Animals ,Hypoglycemic Agents ,030304 developmental biology ,Hepatology ,business.industry ,Liraglutide ,Cholesterol ,dyslipidemia ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,medicine.disease ,Lipid Metabolism ,drug development ,Diet ,Mice, Inbred C57BL ,chemistry ,dietary model ,Steatosis ,Steatohepatitis ,Insulin Resistance ,business ,Dyslipidemia ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Nonalcoholic steatohepatitis (NASH) is an emerging health problem worldwide. However, efficacious pharmacological treatment for NASH is lacking. A major issue for preclinical evaluation of potential therapeutics for NASH is the limited number of appropriate animal models, i.e., models that do not require long-term dietary intervention and adequately mimic disease progression in humans. The present study aimed to evaluate a 3-wk dietary mouse model of NASH and validate it by studying the effects of liraglutide, a compound in advanced clinical development for NASH. C57BL6/J mice were fed a diet high in fat (60%), cholesterol (1.25%), and cholic acid (0.5%), along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC-CDX diet). Histological and biological parameters were measured at 1 and 3 wk. After 1-wk diet induction, liraglutide was administrated daily for 2 wk and then NASH-associated phenotypic aspects were evaluated in comparison with control mice. Prior to treatment with liraglutide, mice fed the HFCC-CDX diet for 1 wk developed liver steatosis and had increased levels of oxidative-stress markers and hepatic and systemic inflammation. For mice not treated with liraglutide, these aspects were even more pronounced after 3 wk of the dietary period, with additional liver insulin resistance and fibrosis. Liraglutide treatment corrected the diet-induced alterations in glucose metabolism and significantly reduced hepatic steatosis and inflammation. This study provides a novel 3-wk dietary model of mice that rapidly develop NASH features, and this model will be suitable for evaluating the therapeutic efficacy of compounds in preclinical drug development for NASH.NEW & NOTEWORTHY We propose a diet high in fat (60%), cholesterol (1.25%), and cholic acid (0.5%) along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC-CDX diet) as a new dietary model of nonalcoholic steatohepatitis. We used the HFCC-CDX model to reproduce the main features of disease development in humans for the purpose of facilitating the rapid screening of drug candidates and prioritizing the more promising candidates for advanced preclinical assessment and subsequent clinical trials.
- Published
- 2019
29. 2004-P: Liraglutide Shows Better Weight Loss and Cardiometabolic Benefits than Lorcaserin and Pioglitazone in a Novel Diet-Induced Obese Rat Model
- Author
-
François Briand, Thierry Sulpice, and Emmanuel Brousseau
- Subjects
Agonist ,medicine.medical_specialty ,Liraglutide ,business.industry ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Type 2 diabetes ,Overweight ,medicine.disease ,Lorcaserin ,Endocrinology ,Weight loss ,Internal medicine ,Internal Medicine ,medicine ,medicine.symptom ,business ,Pioglitazone ,Diet-induced obese ,medicine.drug - Abstract
To evaluate drugs targeting obesity/type 2 diabetes on weight loss and cardiometabolic benefits, and mimic human hyperenergetic nutritional behavior, we set-up a new diet-induced obese (DIO) rat model fed a free choice (FC) diet: control chow (CC) or high fat/cholesterol (HFC) diet, and normal water (NW) or 10% fructose water (FW). After an 8-week FC diet period, rats were treated with vehicle, liraglutide 0.4mg/kg s.c. QD (LIRA, a GLP-1 receptor agonist), lorcaserin 18mg/kg p.o. QD (LORCA, a 5-HT2C receptor agonist) and pioglitazone 10mg/kg p.o. QD (PIO, a PPARgamma agonist) for 5 weeks. FC diet induced high intake of HFC and FW, resulting in significantly higher caloric intake and overweight, as compared with rats fed a CC diet alone. LIRA induced a 12% body weight loss (p In conclusion, LIRA showed superior cardiometabolic benefits than LORCA and PIO in our DIO rat fed a FC diet. This novel model mimicking human overfeeding will be useful to evaluate drugs targeting obesity/type 2 diabetes. Disclosure F. Briand: Employee; Self; Physiogenex. E. Brousseau: Employee; Self; Physiogenex. T. Sulpice: Employee; Self; Physiogenex.
- Published
- 2019
30. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin
- Author
-
Fredrik Wolfhagen Sand, Elisabeth D. Galsgaard, Sisse A Nørgaard, Henrik Søndergaard, Thierry Sulpice, Dorte Bratbo Sørensen, and François Briand
- Subjects
0301 basic medicine ,Blood Glucose ,medicine.medical_specialty ,Time Factors ,High-protein diet ,medicine.disease_cause ,Kidney ,Nephropathy ,Diabetic nephropathy ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Glucosides ,Sodium-Glucose Transporter 2 ,Internal medicine ,medicine ,Animals ,Diabetic Nephropathies ,Dapagliflozin ,Benzhydryl Compounds ,Sodium-Glucose Transporter 2 Inhibitors ,Pharmacology ,business.industry ,Body Weight ,medicine.disease ,Db/db Mouse ,030104 developmental biology ,Endocrinology ,chemistry ,Gene Expression Regulation ,Albuminuria ,Diet, High-Protein ,Disease Progression ,medicine.symptom ,SGLT2 Inhibitor ,business ,030217 neurology & neurosurgery ,Glomerular hyperfiltration ,Biomarkers - Abstract
The widely used db/db mouse as a model of diabetic nephropathy (DN) only mimics the early changes in human DN with a slow disease progression. Since high protein diet (HPD) has been reported to affect progression of nephropathy in both humans and mice, we investigated whether HPD could accelerate nephropathy in db/db mice. Diabetic (C57BLKS-Leprdb/db) and non-diabetic (C57BLKS-Leprdb/+) mice were fed either HPD (60 kcal% protein) or control diet (22 kcal% protein), from 7 to 22 weeks of age. In db/db mice, HPD was found to significantly increase all measured readouts of renal injury including albuminuria, renal hypertrophy, mesangial expansion and expression of a panel of DN related markers, including KIM-1, Ki67 and Collagen III, which increased on both gene and protein levels. Furthermore, HPD activated the Renin-angiotensin system significantly and increased hyperfiltration, measured as reduced plasma Cystatin C. Usefulness of the HPD db/db mouse as a model for faster drug efficacy studies was investigated in a 5-week treatment study with the SGLT2 inhibitor, dapagliflozin. Expectedly, dapagliflozin normalised blood glucose levels and improved glucose intolerance in both HPD and control diet mice. Only HPD db/db mice, not the control diet db/db mice, showed clear hyperfiltration that was significantly reduced with dapagliflozin treatment at both 2 and 4 weeks of treatment. In conclusion, these studies confirm that HPD can significantly accelerate progression of nephropathy in db/db mice, and that this model could be useful for rapid evaluation of drug targets with potential to ameliorate features of DN, especially glomerular hyperfiltration.
- Published
- 2019
31. Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model
- Author
-
Emmanuel Brousseau, Clément Costard, Rémy Burcelin, Thierry Sulpice, François Briand, Natalia Breyner, Caroline Dubroca, and Julie Maupoint
- Subjects
Blood Glucose ,Male ,0301 basic medicine ,medicine.medical_specialty ,Dietary Sugars ,Fructose ,Overweight ,Diet, High-Fat ,Lorcaserin ,Cholesterol, Dietary ,Rats, Sprague-Dawley ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Insulin resistance ,Internal medicine ,medicine ,Animals ,Hypoglycemic Agents ,Obesity ,Pharmacology ,Liraglutide ,business.industry ,Cholesterol ,Body Weight ,medicine.disease ,Disease Models, Animal ,030104 developmental biology ,Endocrinology ,chemistry ,Anti-Obesity Agents ,Insulin Resistance ,medicine.symptom ,business ,Diet-induced obese ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Lorcaserin (LORCA) and liraglutide (LIRA) were evaluated in a novel diet-induced obese (DIO) rat model fed a free choice (FC) diet, that presents rats with the options between control chow (CC) or high fat/cholesterol (HFC) diet, and normal water (NW) or 10% fructose water (FW). After 8 weeks of FC diet-induced obesity/insulin resistance, rats were maintained on FC diet and treated daily for 5 weeks with vehicle, LORCA 18 mg/kg orally or LIRA 0.4 mg/kg subcutaneously. Compared to CC diet, FC diet resulted in higher intake of HFC and FW, and significantly higher caloric intake and overweight. LIRA induced a lower HFC/FW and higher CC/NW intake, a 12% body weight loss (P 0.01 vs. FC) and 40% lower visceral fat mass (P 0.001). LORCA only reduced HFC intake and body weight gain (P 0.001 vs. FC). FC diet raised HOMA-IR index and plasma leptinemia by 66% and 165% (both P 0.05 vs. CC), which were 50% and 70% lower with LIRA (both P 0.05 vs. FC), but unchanged by LORCA. LIRA and LORCA significantly improved FC diet-induced glucose intolerance. Only LIRA reduced liver fatty acids, triglycerides, and cholesterol by 68, 71 and 51% (all P 0.001). FC diet also induced a diastolic dysfunction with reduced E/A ratio (P 0.01 vs. CC), which was improved by LIRA and LORCA (both P 0.01 vs. FC). LIRA also raised fractional shortening (P 0.01 vs. FC). Overall, LIRA showed superior cardiometabolic benefits than LORCA in DIO rats under the FC diet, a model that will be useful to evaluate novel drugs targeting obesity and co-morbidities.
- Published
- 2020
32. A 3-week nonalcoholic steatohepatitis mouse model allows the rapid evaluation of liraglutide and elafibranor benefits on NASH
- Author
-
Thierry Sulpice, Lucile Bonada, Thibaut Duparc, Rémy Burcelin, François Briand, Laurent O. Martinez, and Christophe Heymes
- Subjects
Nonalcoholic steatohepatitis ,medicine.medical_specialty ,Endocrinology ,business.industry ,Liraglutide ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,medicine ,Elafibranor ,business ,Gastroenterology ,medicine.drug - Published
- 2020
33. Liraglutide Shows Better Cardiometabolic Benefits Than Lorcaserin in a Novel Free Choice Diet-Induced Obese Rat Model
- Author
-
Thierry Sulpice, Emmanuel Brousseau, and François Briand
- Subjects
medicine.medical_specialty ,Endocrinology ,Liraglutide ,business.industry ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,Rat model ,medicine ,business ,Diet-induced obese ,Lorcaserin ,medicine.drug - Published
- 2020
34. Differential Impacts of Insulin Analogs Lispro and Glulisine on Glucose and Lipid Homeostasis during Hyperinsulinemic Euglycemic Clamp in Streptozotocin-Induced Diabetic Rats
- Author
-
Rémy Burcelin, Emmanuel Brousseau, Thierry Sulpice, and François Briand
- Subjects
medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,Insulin ,medicine.medical_treatment ,Lipid metabolism ,medicine.disease ,Streptozotocin ,Clamp ,Endocrinology ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,Lipolysis ,business ,Cholesterol homeostasis ,Perfusion ,medicine.drug - Abstract
In addition to their benefits on glycemia, the specific actions of insulin analogs on glucose and lipid metabolism should be depicted. Here we analyzed the effects of Lispro (LIS) and Glulisine (GLU) insulin-analogs in diabetic rats. Diabetes was induced in Wistar male rats following an i.v. injection of streptozotocin (STZ) at 60mg/kg. Conscious rats underwent a 2-hour hyperinsulinemic (LIS or GLU at 0.8U/kg/h) euglycemic clamp with a constant infusion of 3H-glucose (4µCi/kg/min), with n=8 rats per each group. Glycemia was monitored continuously to adjust glucose infusion rate (GIR) to maintain euglycemia during the LIS or GLU perfusion. Blood, muscle and liver samples were collected for biochemical and radioactivity analysis. Compared to GLU, mean GIR was 51% higher in LIS treated rats (LIS: 18 +/- 1mg/kg/min, GLU: 12 +/- 1 mg/kg/min, p In conclusion, hyperinsulinemic euglycemic clamps in STZ rats enabled to detect a strong inhibition of hepatic glucose production by LIS, while GLU better suppresses lipolysis. Our experimental setting should help to differentiate other insulin analogs and dissect their mechanisms of action. Disclosure F. Briand: Employee; Self; Physiogenex S.A.S.. Stock/Shareholder; Self; Physiogenex S.A.S. E. Brousseau: Employee; Self; Physiogenex S.A.S. R. Burcelin: Stock/Shareholder; Self; Physiogenex S.A.S. T. Sulpice: Employee; Self; Physiogenex S.A.S.. Stock/Shareholder; Self; Physiogenex S.A.S..
- Published
- 2018
35. Abstract 545: Evolocumab Alters LDL-cholesterol Levels but Not Glycemic Profile and Liver Lipids in Chow Fed and High fat/Cholesterol/Fructose Fed Golden Syrian Hamsters
- Author
-
Noémie Burr, Thierry Sulpice, Emmanuel Brousseau, and François Briand
- Subjects
medicine.medical_specialty ,Chemistry ,PCSK9 ,Fatty liver ,Subtilisin ,Fructose ,Carbohydrate metabolism ,Proprotein convertase ,medicine.disease ,Evolocumab ,chemistry.chemical_compound ,Endocrinology ,Internal medicine ,medicine ,Cardiology and Cardiovascular Medicine ,Glycemic - Abstract
Background: Beside its effect on LDL-cholesterol levels, proprotein convertase subtilisin/kexin9 (PCSK9) could also be linked to glucose metabolism and non-alcoholic fatty liver diseases. Here we evaluated whether Evolocumab (EVO), a monoclonal antibody targeting PCSK9, may alter glycemic profile and liver lipids in hamsters. Methods: Hamsters were maintained on either a control chow (CC) or high fat/cholesterol/fructose (HFCF) diet for 5 weeks. After 2 weeks of diet, hamsters were randomized into 2 groups, control or EVO at 30mg/kg s.c. once weekly for 3 weeks, to evaluate the effects on lipoprotein/glycemic profiles, and liver lipids. Results: When compared with CC diet, HFCF diet significantly increased total cholesterol and LDL-cholesterol levels by 87% and 102%. Hamsters fed the HFCF diet also showed higher HOMA-IR index of insulin resistance, higher blood glucose area under the curve (AUC) during an oral glucose tolerance test (OGTT), and higher liver lipids (triglycerides: +197%, total cholesterol: +421%, both p Conclusion: Our data indicate that diet-induced insulin resistance and liver steatosis in hamsters are not associated with elevated plasma PCSK9 levels, and are not altered by Evolocumab. Whether these results are specific to our hamster model and can translate to humans remains to be further investigated.
- Published
- 2018
36. FRI-285-The benchmarks obeticholic acid and elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models
- Author
-
Briand, Francois, primary, Emmanuel, Brousseau, additional, Nourdine, Faresse, additional, and Thierry, Sulpice, additional
- Published
- 2019
- Full Text
- View/download PDF
37. Evaluation of Antiatherogenic Properties of Ezetimibe Using 3 H-Labeled Low-Density-Lipoprotein Cholesterol and 99m Tc-cAbVCAM1–5 SPECT in ApoE −/− Mice Fed the Paigen Diet
- Author
-
Audrey Soubies, Alexis Broisat, Mitra Ahmadi, Emmanuel Brousseau, Laurent Dumas, Laurent Riou, Romain Clerc, Tony Lahoutte, Sandrine Bacot, Pascale Perret, Daniel Fagret, Thierry Sulpice, Christopher Montemagno, François Briand, Nick Devoogdt, Catherine Ghezzi, Gilles Barone-Rochette, Radiopharmaceutiques biocliniques (LRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Advanced Accelerator Applications [Saint-Genis-Pouilly, France], Physiogenex, In vivo Cellular and Molecular Imaging Laboratory [Brussel, Belgium] (ICMI), Vrije Universiteit Brussel (VUB), and Perret, Pascale
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Apolipoprotein B ,[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine ,030204 cardiovascular system & hematology ,Proinflammatory cytokine ,[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine ,Excretion ,99mTc-cAbVCAM1–5 ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Ezetimibe ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,LDL-cholesterol catabolism ,VCAM-1 ,biology ,Cholesterol ,Catabolism ,Cholic acid ,3. Good health ,030104 developmental biology ,Endocrinology ,chemistry ,Intestinal cholesterol absorption ,biology.protein ,lipids (amino acids, peptides, and proteins) ,atherosclerosis ,medicine.drug ,ezetimibe - Abstract
International audience; The addition of ezetimibe, an intestinal cholesterol absorption inhibitor, to statin therapy has recently shown clinical benefits in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial by reducing low-density-lipoprotein (LDL) cholesterol levels more than statin therapy alone. Here, we investigated the mechanisms by which inhibition of intestinal cholesterol absorption might contribute to the clinically observed reduction in cardiovascular events by evaluating its effect on inflammatory plaque development in apolipoprotein E-/- mice. Methods: Apolipoprotein E-/- mice were fed the Paigen diet (1.25% cholesterol, 0.5% cholic acid, and 15% fat) without or with ezetimibe (7 mg/kg/d) for 6 wk. In a first set of mice (n = 15), we intravenously injected 3H-cholesteryl oleate-labeled human LDL to test whether ezetimibe promotes LDL-derived cholesterol fecal excretion. In a second set (n = 20), we used the imaging agent 99mTc-cAbVCAM1-5 to evaluate expression of an inflammatory marker, vascular cell adhesion molecule 1 (VCAM-1), in atherosclerotic plaques. In a third set (n = 21), we compared VCAM-1 expression with 99mTc-cAbVCAM1-5 uptake in various tissues. Results: Mice treated with ezetimibe showed a 173% higher LDL-cholesteryl ester plasma disappearance rate (P < 0.001 vs. control) after 3H-cholesteryl oleate-labeled LDL injection. At 96 h after injection, the hepatic fraction of 3H-tracer was 61% lower in mice treated with ezetimibe (P < 0.001). Meanwhile, LDL-derived 3H-cholesterol excretion in the feces was 107% higher (P < 0.001). The antiatherogenic effect of ezetimibe monitored by 99mTc-cAbVCAM1-5 SPECT showed a 49% reduction in aortic tracer uptake (percentage injected dose per cubic centimeter, 0.95 ± 0.04 vs. 1.87 ± 0.11; P < 0.01). In addition to hypercholesterolemia, the proinflammatory Paigen diet significantly increased VCAM-1 expression with respect to the control group in various tissues, including the aorta, and this expression correlated strongly with 99mTc-cAbVCAM1-5 uptake (r = 0.75; P < 0.05). Conclusion: Inhibition of intestinal cholesterol absorption with ezetimibe promotes antiatherosclerotic effects through increased LDL cholesterol catabolism and LDL-derived cholesterol fecal excretion and reduces inflamed atherosclerotic plaques. These mechanisms may contribute to the benefits of adding ezetimibe to a statin therapy.
- Published
- 2017
38. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model
- Author
-
Emmanuel Brousseau, François Briand, Thierry Sulpice, Rémy Burcelin, and Marjolaine Quinsat
- Subjects
0301 basic medicine ,CD36 Antigens ,Male ,medicine.medical_specialty ,Hamster ,Cholesterol 7 alpha-hydroxylase ,Chenodeoxycholic Acid ,03 medical and health sciences ,chemistry.chemical_compound ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Cricetinae ,Cholesterylester transfer protein ,Medicine ,Animals ,Dyslipidemias ,Pharmacology ,biology ,business.industry ,Cholesterol ,Body Weight ,Cholesterol, HDL ,Obeticholic acid ,Cholesterol, LDL ,medicine.disease ,eye diseases ,Cholesterol Ester Transfer Proteins ,Diet ,Rats ,Disease Models, Animal ,030104 developmental biology ,Endocrinology ,chemistry ,Biochemistry ,Gene Expression Regulation ,Liver ,Receptors, LDL ,biology.protein ,Insulin Resistance ,business ,CYP8B1 ,Dyslipidemia ,Lipoprotein - Abstract
The use of rat and mouse models limits the translation to humans for developing novel drugs targeting nonalcoholic steatohepatitis (NASH). Obeticholic acid (OCA) illustrates this limitation since its dyslipidemic effect in humans cannot be observed in these rodents. Conversely, Golden Syrian hamsters have a lipoprotein metabolism mimicking human dyslipidemia since it does express the cholesteryl ester transfer protein (CETP). We therefore developed a Diet-Induced NASH (DIN) hamster model and evaluated the impact of OCA. Compared with chow fed controls, hamsters fed for 20 weeks with a free-choice (FC) diet, developed obesity, insulin resistance, dyslipidemia and NASH (microvesicular steatosis, inflammation, hepatocyte ballooning and perisinusoidal to bridging fibrosis). After 20 weeks of diet, FC fed hamsters were treated without or with obeticholic acid (15mg/kg/day) for 5 weeks. Although a non-significant trend towards higher dietary caloric intake was observed, OCA significantly lowered body weight after 5 weeks of treatment. OCA significantly increased CETP activity and LDL-C levels by 20% and 27%, and reduced HDL-C levels by 20%. OCA blunted hepatic gene expression of Cyp7a1 and Cyp8b1 and reduced fecal bile acids mass excretion by 64% (P < 0.05). Hamsters treated with OCA showed a trend towards higher scavenger receptor Class B type I (SR-BI) and lower LDL-receptor hepatic protein expression. OCA reduced NAS score for inflammation (P < 0.01) and total NAS score, although not significantly. Compared to mouse and rat models, the DIN hamster replicates benefits and side effects of OCA as observed in humans, and should be useful for evaluating novel drugs targeting NASH.
- Published
- 2017
39. Artemisinins Target GABA A Receptor Signaling and Impair α Cell Identity
- Author
-
Sara Sdelci, Tibor Harkany, Keiryn L. Bennett, Kilian Huber, Patrick Collombat, Christian Honoré, Florian M. Pauler, Matthias Farlik, Ekaterine Berishvili, Monica Courtney, Igor Baburin, Stefan Kubicek, Nicole Schmitner, Jin Li, Steffen Hering, Peter Májek, Jacob Hecksher-Sørensen, Thierry Sulpice, Martin Distel, Robin A. Kimmel, Charles-Hugues Lardeau, Manuela Gridling, Johanna Klughammer, Camilla Ingvorsen, Alexey Stukalov, Christoph Bock, Andhira Vieira, François Briand, Giulio Superti-Furga, Roman A. Romanov, Thomas Frogne, Dirk Meyer, Caterina Sturtzel, Thomas Penz, Fabio Avolio, Katja Parapatics, Jacques Colinge, Andreas Spittler, Charlotte Barbieux, Tamara Casteels, Harbin Engineering University (HRBEU), Research Center for Molecular Medicine of the Austrian Academy of Sciences [Vienna, Austria] (CeMM ), Austrian Academy of Sciences (OeAW), CeMM Research Center for Molecular Medicine [Vienna, Austria], Novo Nordisk A/S , Danemark, Novo Nordisk, Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Institute for Research on Cancer and Aging, Nice (IRCAN), INSERM, U1081, CNRS UMR 7284, Nice, Innsbruck Medical University [Austria] (IMU), Leopold Franzens Universität Innsbruck - University of Innsbruck, Medizinische Universität Wien = Medical University of Vienna, Karolinska Institutet [Stockholm], Tumor Immunology [Vienna, Austria] (Children’s Cancer Research Institute), St. Anna Kinderkrebsforschung e.V. [Vienna, Austria], CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria, Physiological Chemistry, Biocenter, Am Hubland, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), IBM PSSC Montpellier - Innovation Lab., IBM PSSC Montpellier, Physiogenex, University of Geneva [Switzerland], Geneva University Hospital (HUG), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Children’s Cancer Research Institute [Vienna, Austria], University of Vienna [Vienna], Cancer Center Karolinska [Karolinska Institutet] (CCK), Directors's Laboratory, Novo Nordisk Foundation Center for Biosustainability, and Technical University of Denmark [Lyngby] (DTU)
- Subjects
0301 basic medicine ,insulin secretion ,Artemisinins/administration & dosage/pharmacology ,β cell ,Carrier Proteins/metabolism ,Diabetes Mellitus/drug therapy ,Mice ,Single-cell analysis ,Insulin-Secreting Cells ,GABA-receptor signaling ,Insulin ,artemisinins ,gamma-Aminobutyric Acid/metabolism ,Cells, Cultured ,Zebrafish ,gamma-Aminobutyric Acid ,pancreatic endocrine transdifferentiation ,ddc:617 ,biology ,diabetes ,Protein Stability ,Receptors, GABA-A/metabolism ,Transdifferentiation ,Diabetes Mellitus, Type 1/drug therapy/pathology ,3. Good health ,Cell biology ,medicine.anatomical_structure ,Biochemistry ,ARX translocation ,Artemether ,MESH: Animals ,Disease models, animal ,Insulin/Genetics ,Signal transduction ,Artemisinins/Pharmacology ,Single-Cell Analysis ,Signal Transduction ,Cell type ,regenerative medicine ,chemical biology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Cell Transdifferentiation/drug effects ,Article ,General Biochemistry, Genetics and Molecular Biology ,Diabetes Mellitus, Experimental ,Islets of Langerhans ,03 medical and health sciences ,Genetic model ,Protein Stability/drug effects ,Diabetes Mellitus ,medicine ,Homeodomain Proteins/metabolism ,Regeneration ,Animals ,Humans ,Transcription Factors/metabolism ,Transcription factor ,Homeodomain Proteins ,Insulin/genetics/metabolism ,Gephyrin ,Biochemistry, Genetics and Molecular Biology(all) ,Gene Expression Profiling ,Pancreatic islets ,Membrane Proteins ,Islets of Langerhans/drug effects ,Receptors, GABA-A ,gephyrin ,Rats ,Disease Models, Animal ,Diabetes Mellitus, Type 1 ,030104 developmental biology ,Cell Transdifferentiation ,biology.protein ,Membrane Proteins/metabolism ,Carrier Proteins ,Transcription Factors - Abstract
Summary Type 1 diabetes is characterized by the destruction of pancreatic β cells, and generating new insulin-producing cells from other cell types is a major aim of regenerative medicine. One promising approach is transdifferentiation of developmentally related pancreatic cell types, including glucagon-producing α cells. In a genetic model, loss of the master regulatory transcription factor Arx is sufficient to induce the conversion of α cells to functional β-like cells. Here, we identify artemisinins as small molecules that functionally repress Arx by causing its translocation to the cytoplasm. We show that the protein gephyrin is the mammalian target of these antimalarial drugs and that the mechanism of action of these molecules depends on the enhancement of GABAA receptor signaling. Our results in zebrafish, rodents, and primary human pancreatic islets identify gephyrin as a druggable target for the regeneration of pancreatic β cell mass from α cells., Graphical Abstract, Highlights • Artemisinins inhibit ARX function and impair α cell identity • Compounds act by stabilizing gephyrin, thus enhancing GABAA receptor signaling • Artemisinins increase β cell mass in zebrafish and rodent models • Functional and transcriptional data indicate a conserved phenotype in human islets, The anti-malarial drug Artemisinin can drive the in vivo conversion of pancreatic α cells into functional β-like cells through enhanced GABA signaling and may have potential as a therapeutic for diabetes.
- Published
- 2017
40. Cathepsin S inhibition lowers blood glucose levels in mice
- Author
-
Karine Clément, Jean-Charles Lafarge, Véronique Pelloux, Guo-Ping Shi, Thierry Sulpice, Michèle Guerre-Millo, Nicolas Venteclef, Guido Hartmann, Maria Pini, and Gabriela Orasanu
- Subjects
Blood Glucose ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Respiratory chain ,Adipose tissue ,Type 2 diabetes ,Biology ,Diet, High-Fat ,Mice ,Oxygen Consumption ,Downregulation and upregulation ,Internal medicine ,Internal Medicine ,medicine ,Animals ,Insulin ,Glucose homeostasis ,Obesity ,Cathepsin S ,Mice, Knockout ,CATS ,medicine.disease ,Cathepsins ,Endocrinology ,Knockout mouse ,Insulin Resistance - Abstract
Cathepsin S (CatS) belongs to a family of proteases that have been implicated in several disease processes. We previously identified CatS as a protein that is markedly overexpressed in adipose tissue of obese individuals and downregulated after weight loss and amelioration of glycaemic status induced by gastric bypass surgery. This prompted us to test whether the protease contributes to the pathogenesis of type 2 diabetes using mouse models with CatS inactivation. CatS knockout mice and wild-type mice treated with orally active small-molecule CatS inhibitors were fed chow or high-fat diets and explored for change in glycaemic status. CatS deletion induced a robust reduction in blood glucose, which was preserved in diet-induced obesity and with ageing and was recapitulated with CatS inhibition in obese mice. In vivo testing of glucose tolerance, insulin sensitivity and glycaemic response to gluconeogenic substrates revealed that CatS suppression reduced hepatic glucose production despite there being no improvement in insulin sensitivity. This phenotype relied on downregulation of gluconeogenic gene expression in liver and a lower rate of hepatocellular respiration. Mechanistically, we found that the protein ‘regulated in development and DNA damage response 1’ (REDD1), a factor potentially implicated in reduction of respiratory chain activity, was overexpressed in the liver of mice with CatS deficiency. Our results revealed an unexpected metabolic effect of CatS in promoting pro-diabetic alterations in the liver. CatS inhibitors currently proposed for treatment of autoimmune diseases could help to lower hepatic glucose output in obese individuals at risk for type 2 diabetes.
- Published
- 2014
41. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters
- Author
-
Clément Costard, Sylvie Sordello, Thierry Sulpice, Bénédicte Prunet-Marcassus, Quentin Thieblemont, François Briand, and Elodie Muzotte
- Subjects
Male ,medicine.medical_specialty ,Glucose uptake ,Drug Evaluation, Preclinical ,AMP-Activated Protein Kinases ,Deoxyglucose ,Carbohydrate metabolism ,Feces ,Random Allocation ,chemistry.chemical_compound ,Apolipoproteins E ,Insulin resistance ,High-density lipoprotein ,Species Specificity ,Cricetinae ,Internal medicine ,Cholesterylester transfer protein ,medicine ,Animals ,Homeostasis ,Glucose homeostasis ,Muscle, Skeletal ,CETP inhibitor ,Dyslipidemias ,Apolipoprotein A-I ,Mesocricetus ,biology ,Chemistry ,Anticholesteremic Agents ,Cholesterol, HDL ,Torcetrapib ,medicine.disease ,Cholesterol Ester Transfer Proteins ,Enzyme Activation ,Disease Models, Animal ,Glucose ,Endocrinology ,Hyperglycemia ,Quinolines ,biology.protein ,Diet, Atherogenic ,lipids (amino acids, peptides, and proteins) ,Insulin Resistance ,Cardiology and Cardiovascular Medicine - Abstract
We investigated whether raising HDL-cholesterol levels with cholesteryl ester transfer protein (CETP) inhibition improves glucose homeostasis in dyslipidemic and insulin resistant hamsters. Compared with vehicle, torcetrapib 30 mg/kg/day (TOR) administered for 10 days significantly increased by ∼40% both HDL-cholesterol levels and 3 H-tracer appearance in HDL after 3 H-cholesterol labeled macrophages i.p. injection. TOR significantly reduced fasting plasma triglycerides, glycerol and free fatty acids levels by 65%, 31% and 23%, respectively. TOR also reduced blood glucose levels and plasma insulin by 20% and 49% respectively, which led to a 60% reduction in HOMA-IR index (all p 3 H-2-deoxyglucose and insulin injection, TOR significantly increased glucose uptake in oxidative soleus muscle, liver and heart by 26, 33 and 70%, respectively. Raising HDL levels with the CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters. Whether similar effect would be observed with other CETP inhibitors should be investigated.
- Published
- 2014
42. Evaluation of Antiatherogenic Properties of Ezetimibe Using
- Author
-
Laurent S, Dumas, François, Briand, Romain, Clerc, Emmanuel, Brousseau, Christopher, Montemagno, Mitra, Ahmadi, Sandrine, Bacot, Audrey, Soubies, Pascale, Perret, Laurent M, Riou, Nick, Devoogdt, Tony, Lahoutte, Gilles, Barone-Rochette, Daniel, Fagret, Catherine, Ghezzi, Thierry, Sulpice, and Alexis, Broisat
- Subjects
Mice, Knockout ,Tomography, Emission-Computed, Single-Photon ,Anticholesteremic Agents ,Reproducibility of Results ,Technetium ,Mice, Transgenic ,Cholesterol, LDL ,Atherosclerosis ,Diet, High-Fat ,Ezetimibe ,Tritium ,Sensitivity and Specificity ,Mice, Inbred C57BL ,Feces ,Mice ,Apolipoproteins E ,Treatment Outcome ,Isotope Labeling ,Animals ,Female ,Drug Monitoring - Abstract
The addition of ezetimibe, an intestinal cholesterol absorption inhibitor, to statin therapy has recently shown clinical benefits in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial by reducing low-density-lipoprotein (LDL) cholesterol levels more than statin therapy alone. Here, we investigated the mechanisms by which inhibition of intestinal cholesterol absorption might contribute to the clinically observed reduction in cardiovascular events by evaluating its effect on inflammatory plaque development in apolipoprotein E
- Published
- 2016
43. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- Author
-
Noémie Burr, François Briand, Isabelle Urbain, Michael Mark, Clément Costard, Eric Mayoux, Emmanuel Brousseau, and Thierry Sulpice
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Diet, High-Fat ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Glucosides ,Internal medicine ,Cricetinae ,Internal Medicine ,medicine ,Empagliflozin ,Animals ,Hypoglycemic Agents ,Benzhydryl Compounds ,Intestinal Mucosa ,Dyslipidemias ,Glycogen ,Mesocricetus ,Chemistry ,Cholesterol ,Catabolism ,Metabolism ,Cholesterol, LDL ,Lipid Metabolism ,Intestines ,Endocrinology ,LDL receptor ,Intestinal cholesterol absorption ,Ketone bodies ,lipids (amino acids, peptides, and proteins) ,Energy Metabolism - Abstract
In clinical trials, a small increase in LDL cholesterol has been reported with sodium–glucose cotransporter 2 (SGLT2) inhibitors. The mechanisms by which the SGLT2 inhibitor empagliflozin increases LDL cholesterol levels were investigated in hamsters with diet-induced dyslipidemia. Compared with vehicle, empagliflozin 30 mg/kg/day for 2 weeks significantly reduced fasting blood glucose by 18%, with significant increase in fasting plasma LDL cholesterol, free fatty acids, and total ketone bodies by 25, 49, and 116%, respectively. In fasting conditions, glycogen hepatic levels were further reduced by 84% with empagliflozin, while 3-hydroxy-3-methylglutaryl-CoA reductase activity and total cholesterol hepatic levels were 31 and 10% higher, respectively (both P < 0.05 vs. vehicle). A significant 20% reduction in hepatic LDL receptor protein expression was also observed with empagliflozin. Importantly, none of these parameters were changed by empagliflozin in fed conditions. Empagliflozin significantly reduced the catabolism of 3H-cholesteryl oleate–labeled LDL injected intravenously by 20%, indicating that empagliflozin raises LDL levels through reduced catabolism. Unexpectedly, empagliflozin also reduced intestinal cholesterol absorption in vivo, which led to a significant increase in LDL- and macrophage-derived cholesterol fecal excretion (both P < 0.05 vs. vehicle). These data suggest that empagliflozin, by switching energy metabolism from carbohydrate to lipid utilization, moderately increases ketone production and LDL cholesterol levels. Interestingly, empagliflozin also reduces intestinal cholesterol absorption, which in turn promotes LDL- and macrophage-derived cholesterol fecal excretion.
- Published
- 2016
44. High-Fat and Fructose Intake Induces Insulin Resistance, Dyslipidemia, and Liver Steatosis and Alters In Vivo Macrophage-to-Feces Reverse Cholesterol Transport in Hamsters
- Author
-
Quentin Thieblemont, Thierry Sulpice, Elodie Muzotte, and François Briand
- Subjects
Male ,medicine.medical_specialty ,Medicine (miscellaneous) ,Fructose ,Diet, High-Fat ,Feces ,chemistry.chemical_compound ,Insulin resistance ,Cricetinae ,Internal medicine ,medicine ,Animals ,Triglycerides ,Dyslipidemias ,Metabolic Syndrome ,Nutrition and Dietetics ,Mesocricetus ,biology ,Cholesterol ,Macrophages ,Reverse cholesterol transport ,Fatty liver ,Biological Transport ,medicine.disease ,biology.organism_classification ,Cholesterol Ester Transfer Proteins ,Up-Regulation ,Fatty Liver ,Disease Models, Animal ,Kinetics ,Endocrinology ,Liver ,chemistry ,Intestinal cholesterol absorption ,lipids (amino acids, peptides, and proteins) ,Insulin Resistance ,Metabolic syndrome ,Dyslipidemia - Abstract
Reverse cholesterol transport (RCT) promotes the egress of cholesterol from peripheral tissues to the liver for biliary and fecal excretion. Although not demonstrated in vivo, RCT is thought to be impaired in patients with metabolic syndrome, in which liver steatosis prevalence is relatively high. Golden Syrian hamsters were fed a nonpurified (CON) diet and normal drinking water or a high-fat (HF) diet containing 27% fat, 0.5% cholesterol, and 0.25% deoxycholate as well as 10% fructose in drinking water for 4 wk. Compared to CON, the HF diet induced insulin resistance and dyslipidemia, with significantly higher plasma non-HDL-cholesterol concentrations and cholesteryl ester transfer protein activity. The HF diet induced severe liver steatosis, with significantly higher cholesterol and TG levels compared to CON. In vivo RCT was assessed by i.p. injecting ³H-cholesterol labeled macrophages. Compared to CON, HF hamsters had significantly greater ³H-tracer recoveries in plasma, but not HDL. After 72 h, ³H-tracer recovery in HF hamsters was 318% higher in liver and 75% lower in bile (P < 0.01), indicating that the HF diet impaired hepatic cholesterol fluxes. However, macrophage-derived cholesterol fecal excretion was 45% higher in HF hamsters than in CON hamsters. This effect was not related to intestinal cholesterol absorption, which was 89% higher in HF hamsters (P < 0.05), suggesting a possible upregulation of transintestinal cholesterol excretion. Our data indicate a significant increase in macrophage-derived cholesterol fecal excretion in a hamster model of metabolic syndrome, which may not compensate for the diet-induced dyslipidemia and liver steatosis.
- Published
- 2012
45. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
- Author
-
Sheng-Ping Wang, David G. McLaren, Thomas P. Roddy, Karen Gagen, Ying Chen, Thomas Hankemeier, Brian K. Hubbard, Rob J. Vreeken, Douglas G. Johns, Vinit Shah, Thierry Sulpice, Jose Castro-Perez, and François Briand
- Subjects
Male ,medicine.medical_specialty ,cholesteryl ester transfer protein ,QD415-436 ,Biology ,Biochemistry ,Cell Line ,chemistry.chemical_compound ,Feces ,Mice ,Endocrinology ,High-density lipoprotein ,Anacetrapib ,Internal medicine ,Cricetinae ,Cholesterylester transfer protein ,medicine ,Animals ,Research Articles ,Oxazolidinones ,Dyslipidemias ,Triglyceride ,Cholesterol ,Macrophages ,Reverse cholesterol transport ,Cholic acid ,Biological Transport ,Cell Biology ,Cholesterol Ester Transfer Proteins ,chemistry ,high density lipoprotein ,Cholesteryl ester ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Lipoproteins, HDL ,low density lipoprotein ,cholesterol efflux - Abstract
Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester (CE) and triglyceride between HDL and apoB-containing lipoproteins. Anacetrapib (ANA), a reversible inhibitor of CETP, raises HDL cholesterol (HDL-C) and lowers LDL cholesterol in dyslipidemic patients; however, the effects of ANA on cholesterol/lipoprotein metabolism in a dyslipidemic hamster model have not been demonstrated. To test whether ANA (60 mg/kg/day, 2 weeks) promoted reverse cholesterol transport (RCT), ³H-cholesterol-loaded macrophages were injected and (3)H-tracer levels were measured in HDL, liver, and feces. Compared to controls, ANA inhibited CETP (94%) and increased HDL-C (47%). ³H-tracer in HDL increased by 69% in hamsters treated with ANA, suggesting increased cholesterol efflux from macrophages to HDL. ³H-tracer in fecal cholesterol and bile acids increased by 90% and 57%, respectively, indicating increased macrophage-to-feces RCT. Mass spectrometry analysis of HDL from ANA-treated hamsters revealed an increase in free unlabeled cholesterol and CE. Furthermore, bulk cholesterol and cholic acid were increased in feces from ANA-treated hamsters. Using two independent approaches to assess cholesterol metabolism, the current study demonstrates that CETP inhibition with ANA promotes macrophage-to-feces RCT and results in increased fecal cholesterol/bile acid excretion, further supporting its development as a novel lipid therapy for the treatment of dyslipidemia and atherosclerotic vascular disease.
- Published
- 2011
46. Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice
- Author
-
Pierre Cattan, Julien Castel, Rémy Burcelin, Aurélie Waget, Daniel J. Drucker, Mattieu Armanet, Melis Karaca, Christophe Magnan, Jens J. Holst, Céline Garret, Thierry Sulpice, Gaëlle Payros, Myriam Masseboeuf, Adriano Maida, Cendrine Cabou, Institut des Maladies Métaboliques et Cardiovasculaires ( I2MC ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Cell Therapy Unit, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Biologie Fonctionnelle et Adaptative ( BFA ), Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Department of Medicine, University of Toronto-Samuel Lunenfeld Research Institute-Mount Sinai Hospital ( MSH ), Physiogenex SAS, Prologue Biotech, PHYSIOGENEX S.A.S, Department of Biomedical Sciences, The panum Institute-University of Copenhagen ( KU ), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Toronto-Samuel Lunenfeld Research Institute-Mount Sinai Hospital [Toronto, Canada] (MSH), Physiogenex, Department of Biomedical Sciences [Copenhagen], Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Simon, Marie Francoise, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Toronto-Mount Sinai Hospital [Toronto, Canada] (MSH)-Samuel Lunenfeld Research Institute, and University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)
- Subjects
MESH : Insulin ,medicine.medical_treatment ,MESH : Vagus Nerve ,MESH : Receptors, Glucagon ,0302 clinical medicine ,Endocrinology ,MESH: Dipeptides ,MESH: Vagus Nerve ,Glucose homeostasis ,MESH: Animals ,[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,MESH : Dipeptidyl-Peptidase IV Inhibitors ,0303 health sciences ,Glucose tolerance test ,MESH: Middle Aged ,MESH: Dipeptidyl-Peptidase IV Inhibitors ,medicine.diagnostic_test ,MESH : Glucagon ,MESH: Glucagon ,digestive, oral, and skin physiology ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,MESH : Adult ,[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Glucagon-like peptide-1 ,3. Good health ,MESH : Pyrazines ,MESH: Pyrazines ,Sitagliptin ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug ,endocrine system ,medicine.medical_specialty ,MESH: Glucose Tolerance Test ,MESH : Male ,MESH : Dipeptides ,MESH : Receptors, Gastrointestinal Hormone ,Incretin ,030209 endocrinology & metabolism ,MESH: Insulin ,MESH : Mice, Inbred C57BL ,Biology ,Sitagliptin Phosphate ,MESH : Glucose Tolerance Test ,MESH: Receptors, Glucagon ,03 medical and health sciences ,MESH: Mice, Inbred C57BL ,Internal medicine ,MESH : Mice ,MESH : Triazoles ,medicine ,MESH : Middle Aged ,MESH: Mice ,Dipeptidyl peptidase-4 ,030304 developmental biology ,MESH: Humans ,MESH: Receptors, Gastrointestinal Hormone ,Insulin ,MESH : Humans ,MESH: Adult ,MESH: Dipeptidyl Peptidase 4 ,MESH : Blood Glucose ,MESH: Male ,MESH: Triazoles ,MESH : Dipeptidyl Peptidase 4 ,MESH: Blood Glucose ,MESH : Animals - Abstract
International audience; Inhibition of dipeptidyl peptidase-4 (DPP-4) activity improves glucose homeostasis through a mode of action related to the stabilization of the active forms of DPP-4-sensitive hormones such as the incretins that enhance glucose-induced insulin secretion. However, the DPP-4 enzyme is highly expressed on the surface of intestinal epithelial cells; hence, the role of intestinal vs. systemic DPP-4 remains unclear. To analyze mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice, we administered low oral doses of the DPP-4 inhibitor sitagliptin that selectively reduced DPP-4 activity in the intestine. Glp1r(-/-) and Gipr(-/-) mice were studied and glucagon-like peptide (GLP)-1 receptor (GLP-1R) signaling was blocked by an i.v. infusion of the corresponding receptor antagonist exendin (9-39). The role of the dipeptides His-Ala and Tyr-Ala as DPP-4-generated GLP-1 and glucose-dependent insulinotropic peptide (GIP) degradation products was studied in vivo and in vitro on isolated islets. We demonstrate that very low doses of oral sitagliptin improve glucose tolerance and plasma insulin levels with selective reduction of intestinal but not systemic DPP-4 activity. The glucoregulatory action of sitagliptin was associated with increased vagus nerve activity and was diminished in wild-type mice treated with the GLP-1R antagonist exendin (9-39) and in Glp1r(-/-) and Gipr(-/-) mice. Furthermore, the dipeptides liberated from GLP-1 (His-Ala) and GIP (Tyr-Ala) deteriorated glucose tolerance, reduced insulin, and increased portal glucagon levels. The predominant mechanism through which DPP-4 inhibitors regulate glycemia involves local inhibition of intestinal DPP-4 activity, activation of incretin receptors, reduced liberation of bioactive dipeptides, and activation of the gut-to-pancreas neural axis.
- Published
- 2011
47. Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters
- Author
-
Thierry Sulpice, Agnès André, Patrick Nguyen, Adamou Boubacar, Morgan Tréguier, François Briand, Thierry Magot, Michel Krempf, and Khadija Ouguerram
- Subjects
medicine.medical_specialty ,biology ,Cholesterol ,Clinical Biochemistry ,Reverse cholesterol transport ,Hamster ,General Medicine ,biology.organism_classification ,medicine.disease ,Biochemistry ,Excretion ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,Cholesterylester transfer protein ,medicine ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Mesocricetus ,Dyslipidemia ,Lipoprotein - Abstract
Eur J Clin Invest 2011; 41 (9): 921–928 Abstract Background Reverse cholesterol transport (RCT) is an anti-atherogenic process by which cholesterol is effluxed from peripheral tissues by high-density lipoprotein (HDL) and returned to the liver for excretion into the bile and faeces. Dyslipidemia is thought to impair RCT through higher triglyceride-rich lipoprotein (TRL), low HDL-cholesterol and higher activity of cholesteryl ester transfer protein (CETP), which transfers cholesteryl esters from HDL to TRL for further hepatic uptake. As CETP pathway would represent a major route in human RCT, we therefore investigated whether diet-induced dyslipidemia impairs RCT in hamster, a CETP-expressing species. Materials and methods Golden Syrian hamsters were fed a chow or chow+0·3% cholesterol diet over 4 weeks. Biochemical parameters and in vivo VLDL-triglycerides secretion (Triton WR-1339 injection) were then measured. In vitro macrophage cholesterol efflux was measured, and in vivo macrophage-to-faeces RCT was also assessed after an intraperitoneal injection of 3H-cholesterol-labelled hamster primary macrophages. Results Cholesterol-enriched diet increased plasma total cholesterol (144%), triglycerides (101%), VLDL-triglycerides secretion (175%), CETP activity (44%) and reduced HDL-cholesterol/total cholesterol ratio by 20% (P
- Published
- 2011
48. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment
- Author
-
Mathieu Bergé, Aurélie Waget, Philippe J. Sansonetti, Natalia F. Smirnova, Thierry Sulpice, Rémy Burcelin, Philippe Langella, Luis G. Bermúdez-Humarán, Nina Rautonen, Christelle Vachoux, Jacques Amar, Pascale Klopp, Chantal Chabo, Arthur C. Ouwehand, Sampo J. Lahtinen, Service d'hypertension artérielle et thérapeutique [CHU Toulouse] (HTA et thérapeutique), Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Unité de recherche d'Écologie et Physiologie du Système Digestif (UEPSD), Institut National de la Recherche Agronomique (INRA), Laboratoire de microbiologie et génétique moléculaires - UMR5100 (LMGM), Centre de Biologie Intégrative (CBI), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Adhésion Bacterienne et Formation de Biofilms, PRES Université de Toulouse, Physiogenex, DuPont Health & Nutrition, Pathogénie Microbienne Moléculaire, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Collège de France - Chaire Microbiologie et Maladies infectieuses, Collège de France (CdF (institution)), Agence Nationale de la Recherche (ANR Floradip, Transflora, Vaiomer), European Commission [241913], Simon, Marie Francoise, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne et Hypertension Artérielle [Toulouse], CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Unité d'Ecologie et de Physiologie du Système Digestif, INRA, Unité d'écologie et de physiologie du système digestif, Laboratoire de microbiologie et génétique moléculaires (LMGM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Chaire Microbiologie et Maladies infectieuses
- Subjects
Bifidobacterium lactis 420 ,obesity ,MESH: Bifidobacterium ,[SDV]Life Sciences [q-bio] ,Lipopolysaccharide Receptors ,M CELLS ,MESH: Nod1 Signaling Adaptor Protein ,Adipose tissue ,Chromosomal translocation ,Bacteremia ,INDUCED INFLAMMATION ,Type 2 diabetes ,MESH: Mice, Knockout ,Bacterial Adhesion ,law.invention ,Probiotic ,Mice ,0302 clinical medicine ,law ,Nod1 Signaling Adaptor Protein ,IMMUNE-RESPONSE ,MESH: Animals ,Intestinal Mucosa ,MESH: Bacteremia ,pathogen-associated molecular pattern receptors ,2. Zero hunger ,Mice, Knockout ,0303 health sciences ,biology ,diabetes ,MESH: Escherichia coli ,MESH: Antigens, CD14 ,GUT MICROBIOTA ,3. Good health ,Bifidobacterium animalis ,[SDV] Life Sciences [q-bio] ,ADIPOSE-TISSUE ,Blood ,Adipose Tissue ,ESCHERICHIA-COLI ,MESH: Intestinal Mucosa ,inflammation ,INDUCED INSULIN-RESISTANCE ,HIGH-FAT-DIET ,INNATE IMMUNITY ,OBESE MICE ,Molecular Medicine ,medicine.symptom ,MESH: Adipose Tissue ,MESH: Bacterial Translocation ,MESH: Diabetes Mellitus, Type 2 ,MESH: Myeloid Differentiation Factor 88 ,Research Article ,CD14 ,030209 endocrinology & metabolism ,Inflammation ,Diet, High-Fat ,Microbiology ,03 medical and health sciences ,Insulin resistance ,MESH: Mice, Inbred C57BL ,MESH: Blood ,medicine ,Escherichia coli ,Animals ,MESH: Bacterial Adhesion ,MESH: Mice ,030304 developmental biology ,Probiotics ,medicine.disease ,biology.organism_classification ,Mice, Inbred C57BL ,MESH: Diet, High-Fat ,Diabetes Mellitus, Type 2 ,Bacterial Translocation ,Immunology ,Myeloid Differentiation Factor 88 ,Bifidobacterium ,MESH: Probiotics - Abstract
International audience; A fat-enriched diet modifies intestinal microbiota and initiates a low-grade inflammation, insulin resistance and type-2 diabetes. Here, we demonstrate that before the onset of diabetes, after only one week of a high-fat diet (HFD), live commensal intestinal bacteria are present in large numbers in the adipose tissue and the blood where they can induce inflammation. This translocation is prevented in mice lacking the microbial pattern recognition receptors Nod1 or CD14, but overtly increased in Myd88 knockout and ob/ob mouse. This 'metabolic bacteremia' is characterized by an increased co-localization with dendritic cells from the intestinal lamina propria and by an augmented intestinal mucosal adherence of non-pathogenic Escherichia coli. The bacterial translocation process from intestine towards tissue can be reversed by six weeks of treatment with the probiotic strain Bifidobacterium animalis subsp. lactis 420, which improves the animals' overall inflammatory and metabolic status. Altogether, these data demonstrate that the early onset of HFD-induced hyperglycemia is characterized by an increased bacterial translocation from intestine towards tissues, fuelling a continuous metabolic bacteremia, which could represent new therapeutic targets.
- Published
- 2011
49. Obeticholic Acid Improves both Non-alcoholic Steato-Hepatitis and Atherosclerosis in Obese, Insulin Resistant LDL-Receptor Knock-out Mouse
- Author
-
Thierry Sulpice, Marjolaine Quinsat, Emmanuel Brousseau, and François Briand
- Subjects
Hepatitis ,medicine.medical_specialty ,business.industry ,Obeticholic acid ,Insulin resistant ,Non alcoholic ,General Medicine ,medicine.disease ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,Knockout mouse ,LDL receptor ,Internal Medicine ,medicine ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
50. Evolocumab Alters LDL-cholesterol Levels, But Not Glycemic Profile and Liver Lipids, in Chow Fed and High Fat/Cholesterol/Fructose Fed Golden Syrian Hamsters
- Author
-
Noémie Burr, Emmanuel Brousseau, François Briand, and Thierry Sulpice
- Subjects
Ldl cholesterol ,medicine.medical_specialty ,Fructose ,General Medicine ,Evolocumab ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,Internal Medicine ,medicine ,Cardiology and Cardiovascular Medicine ,Syrian hamsters ,High fat cholesterol ,Glycemic - Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.